0001493152-16-009896.txt : 20160516 0001493152-16-009896.hdr.sgml : 20160516 20160516161156 ACCESSION NUMBER: 0001493152-16-009896 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160516 DATE AS OF CHANGE: 20160516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immune Therapeutics, Inc. CENTRAL INDEX KEY: 0001559356 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 593226705 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54933 FILM NUMBER: 161653877 BUSINESS ADDRESS: STREET 1: 37 NORTH ORANGE AVENUE STREET 2: SUITE 607 CITY: ORLANDO STATE: FL ZIP: 32801 BUSINESS PHONE: (888) 613-8802 MAIL ADDRESS: STREET 1: 37 NORTH ORANGE AVENUE STREET 2: SUITE 607 CITY: ORLANDO STATE: FL ZIP: 32801 FORMER COMPANY: FORMER CONFORMED NAME: TNI BIOTECH, INC. DATE OF NAME CHANGE: 20121001 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

[ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934

From the transition period from ___________ to ____________

Commission File Number __________________

IMMUNE THERAPEUTICS, INC.

(Exact name of small business issuer as specified in its charter)

Florida		59-3226705
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

37 North Orange Ave, Suite 607, Orlando, FL 32801

(Address of principal executive offices)

888-613-8802

(Issuer’s telephone number)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by a check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer [ ]		Accelerated Filer [ ]

Non-Accelerated Filer [ ]		Smaller Reporting Company [X]

Indicate by a check mark whether the company is a shell company (as defined by Rule 12b-2 of the Exchange Act: Yes [ ] No [X]

As of May 12, 2016 there were 206,913,301 shares of Common Stock outstanding.

TABLE OF CONTENTS

	PART I – FINANCIAL STATEMENTS
Item 1.	Financial Statements	5

Item 2.	Management’s Discussion and Analysis of Financial Conditions and Results of Operations	24

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	30

Item 4.	Controls and Procedures	30

	PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	31

Item 1A.	Risk Factors	31

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	31

Item 3.	Default upon Senior Securities	32

Item 4.	Mine Safety Disclosures

Item 5.	Other Information

Item 6.	Exhibits	33

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained or incorporated by reference in this Quarterly Report on Form 10-Q are considered forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995) concerning our business, results of operations, economic performance and/or financial condition, based on management’s current expectations, plans, estimates, assumptions and projections. Forward-looking statements are included, for example, in the discussions about:

●	strategy;
●	new product discovery and development;
●	current or pending clinical trials;
●	our products’ ability to demonstrate efficacy or an acceptable safety profile;
●	actions by the FDA and other regulatory authorities;
●	product manufacturing, including our arrangements with third-party suppliers;
●	product introduction and sales;
●	royalties and contract revenues;
●	expenses and net income;
●	credit and foreign exchange risk management;
●	liquidity;
●	asset and liability risk management;
●	the outcome of litigation and other proceedings;
●	intellectual property rights and protection;
●	economic factors;
●	competition; and
●	legal risks.

Any statements contained in this report that are not statements of historical fact may be deemed forward-looking statements. Forward-looking statements generally are identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “plans,” “may,” “could,” “will,” “will continue,” “seeks,” “should,” “predict,” “potential,” “outlook,” “guidance,” “target,” “forecast,” “probable,” “possible” or the negative of such terms and similar expressions. Forward-looking statements are subject to change and may be affected by risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update any forward-looking statement in light of new information or future events, except as required by law, although we intend to continue to meet our ongoing disclosure obligations under the U.S. securities laws and other applicable laws.

We caution you that a number of important factors could cause actual results or outcomes to differ materially from those expressed in, or implied by, the forward-looking statements, and therefore you should not place too much reliance on them. These factors include, among others, those described herein, under “Risk Factors” and elsewhere in this Annual Report and in our other public reports filed with the Securities and Exchange Commission. It is not possible to predict or identify all such factors, and therefore the factors that are noted are not intended to be a complete discussion of all potential risks or uncertainties that may affect forward-looking statements. If these or other risks and uncertainties materialize, or if the assumptions underlying any of the forward-looking statements prove incorrect, our actual performance and future actions may be materially different from those expressed in, or implied by, such forward-looking statements. We can offer no assurance that our estimates or expectations will prove accurate or that we will be able to achieve our strategic and operational goals.

Forward-looking statements are based on information we have when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:

●	our lack of operating history;
●	our current and future capital requirements and our ability to satisfy our capital needs;
●	our inability to keep up with industry competition;
●	interpretations of current laws and the passages of future laws;
●	acceptance of our business model by investors and our ability to raise capital;
●	our drug discovery and development activities may not result in products that are approved by the applicable regulatory authorities. Even if our drug candidates do obtain regulatory approval they may never achieve market acceptance or commercial success;
●	our reliance on key personnel, including our ability to attract and retain scientists;
●	our reliance on third party manufacturing to supply drugs for clinical trials and sales;
●	our limited distribution organization with no sales and marketing staff;
●	our being subject to product liability claims;
●	our reliance on key personnel, including our ability to attract and retain scientists;
●	legislation or regulation that may increase the cost of our business or limit our service and product offerings;
●	risks related to our intellectual property, including our ability to adequately protect intellectual property rights;
●	risks related to government regulation, including our ability to obtain approvals for the commercialization of some or all of our drug candidates, and ongoing regulatory obligations and continued regulatory review which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements; and
●	our ability to obtain regulatory approvals in foreign jurisdictions to allow us to market our products internationally.

Moreover, new risks regularly emerge and it is not possible for our management to predict or articulate all risks we face, nor can we assess the impact of all risks on our business or the extent to which any risk, or combination of risks, may cause actual results to differ from those contained in any forward-looking statements. All forward-looking statements included in this prospectus are based on information available to us on the date of this Annual Report. Except to the extent required by applicable laws or rules, we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained above and throughout this Annual Report.

JUMPSTART OUR BUSINESS STARTUPS ACT

We qualify as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2015, the last day of our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

As an emerging growth company, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements that are otherwise applicable to public companies. These provisions include, but are not limited to:

●	being permitted to present only two years of audited financial statements and only two years of related “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this annual report;
●	not being requested to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (“Sarbanes-Oxley Act”);
●	reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and
●	exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

We will remain an emerging growth company until the earliest to occur of: (i) our reporting $1 billion or more in annual gross revenues; (ii) the end of fiscal year 2019; (iii) our issuance, in a three year period, of more than $1 billion in non-convertible debt; and (iv) the end of the fiscal year in which the market value of our common stock held by non-affiliates exceeded $700 million on the last business day of our second fiscal quarter.

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

IMMUNE THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2016			December 31, 2015
	(unaudited)			(Audited)
ASSETS
Current Assets:
Cash and cash equivalents	$	132,187		$	23,149
Accounts receivable		19,660			16,197
Prepaids and other current assets		1,594			-
Total current assets		153,441			39,346

Fixed Assets:
Computer equipment, net of accumulated depreciation of $6,878 and $6,331 respectively		1,135			1,682
Deposits		200			200
Total assets	$	154,776		$	41,228

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current Liabilities:
Accounts payable	$	1,860,361		$	1,924,672
Accrued liabilities		1,641,351			1,281,039
Current portion of notes payable		2,838,200			2,793,701
Total current liabilities		6,339,912			5,999,412

Total Liabilities		6,339,912			5,999,412
Commitments and contingencies (Note 11)
Stockholders’ Deficit:
Common stock - par value $0.0001; 500,000,000 shares authorized; 205,127,530 and 174,850,047 shares issued and outstanding respectively		20,513			17,485
Additional paid in capital		351,290,136			343,434,786
Stock issuances due		1,173,244			1,140,303
Prepaid services		(2,133,286	)		(660,417	)
Accumulated deficit		(354,391,171	)		(347,789,889	)
Equity attributable to common stockholders		(4,040,564	)		(3,857,732	)
Non-controlling interest		(2,144,572	)		(2,100,452	)
Total stockholders’ deficit		(6,185,136	)		(5,958,184	)
Total liabilities and stockholders’ deficit	$	154,776		$	41,228

The accompanying notes are an integral part of these condensed consolidated financial statements.

IMMUNE THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months ended
	March 31, 2016			March 31, 2015

Revenues, net	$	3,463		$	2,070

Operating expenses:
Selling, general and administrative		939,341			401,988
Research and development expense		(18,842	)		177,157
Stock issued for services G&A		1,983,837			2,161,559
Stock issued for services R&D		-			-
Warrant valuation expense		2,078,199			-
Depreciation and amortization expense		547			148,727
Total operating expenses		4,983,082			2,889,431

Loss from operations		(4,979,619	)		(2,887,361	)

Other income (expense):
Interest expense		(301,444	)		(18,045	)
Loss on settlement of debt		(1,364,339	)		-
Total other income (expense)		(1,665,783	)		(18,045	)
Net loss	$	(6,645,402	)	$	(2,905,406	)
Net loss attributable to non-controlling interest		(44,120	)		(124,065	)
Net loss attributable to common shareholders		(6,601,282	)		(2,781,341	)
Basic and diluted loss per share to common shareholders	$	(0.03	)	$	(0.02	)
Weighted average number of shares outstanding		190,923,381			138,795,044

The accompanying notes are an integral part of these condensed consolidated financial statements.

IMMUNE THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE PERIOD ENDED MARCH 31, 2016

(Unaudited)

	Common Stock				Additional Paid-in		Stock to			Prepaid			Accumulated			Non-Controlling
	Shares		Amount		Capital		Be Issued			Services			Deficit			Interest			Total

Balance December 31, 2015		174,850,047	$	17,485	$	343,434,786	$	1,140,303		$	(660,417	)	$	(347,789,889	)	$	(2,100,452	)	$	(5,958,184	)

Issuance of common stock for prepaid services		19,043,000		1,904		3,724,266		(269,466	)		(2,142,535	)		-			-			1,314,169

Amortization of prepaid services		-		-		-		-			669,667			-			-			669,667

Issuance of common stock in exchange for debt		10,921,983		1,093		2,027,915		277,407			-			-			-			2,306,415

Issuance of common stock for cash and exercise of warrants		312,500		31		24,969		25,000			-			-			-			50,000

Issuance of common stock warrants		-		-		2,078,199		-			-			-			-			2,078,199

Net loss		-		-		-		-			-			(6,601,282	)		(44,120	)		(6,645,402	)

Balance as of March 31, 2016		205,127,530		20,513		351,290,136		1,173,244			(2,133,286	)		(354,391,171	)		(2,144,572	)		(6,185,136	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

IMMUNE THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended
	March 31, 2016			March 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(6,645,402	)	$	(2,905,406	)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation		547			668
Amortization		-			148,060
Amortization of stock issued for prepaid services		669,667			2,161,559
Stock issued for services		1,314,169			-
Stock warrant expense		2,078,199			-
Loss on settlement of debt		1,364,339			-
Changes in operating assets and liabilities:
Accounts receivable		(3,463	)		(2,070	)
Accounts payable		139,203			(192,521	)
Accrued liabilities		486,373			32,600
Prepaid expenses and other current assets		(1,594	)		-
Net cash used in operating activities		(597,962	)		(757,110	)

CASH FLOWS FROM INVESTING ACTIVITIES
Net cash used in investing activities		-			-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of stock and exercise of warrants		50,000			95,000
Proceeds from issuance of notes payable		657,000			500,975

Net cash provided by financing activities		707,000			595,975

Net decrease in cash and cash equivalents		109,038			(161,135	)
Cash and cash equivalents at beginning of period		23,149			191,987
Cash and cash equivalents at end of period	$	132,817		$	30,852

The accompanying notes are an integral part of these condensed consolidated financial statements.

IMMUNE THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended
	March 31, 2016		March 31, 2015
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

Cash paid for interest	$	7,050	$	4,500

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

Issuance of common stock in exchange for debt and accrued interest	$	2,306,415	$	-

The accompanying notes are an integral part of these condensed consolidated financial statements.

Immune Therapeutics, Inc. and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2016

(Unaudited)

1. Organization and Description of Business

Immune Therapeutics, Inc. (the “Company”) was initially incorporated in Florida on December 2, 1993 as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”).

On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2014 changing our name to Immune Therapeutics, Inc.

The Company currently operates out of Orlando, Florida. In July 2012, the Company’s focus turned to acquiring patents that would protect and advance the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (“LDN”) and Methionine [Met5]-enkephalin (“MENK”). The Company’s therapies are believed to stimulate and/or regulate the immune system in such a way that they provide the potential to treat a variety of diseases. We believe our therapies may be able to correct abnormalities or deficiencies in the immune system in diseases such as HIV infection, autoimmune disease, immune disorders, or cancer; all of which can lead to disease progression and life-threatening situations when the immune system is not functioning optimally.

In October 2012, the Company formed TNI BioTech International, Ltd., a BVI company in Tortola, British Virgin Islands, which was set up to allow the Company to market and sell LDN in those countries outside the U.S. in which we have been able to obtain approval to sell the Company’s products.

In August 2013, the Company formed its United Kingdom subsidiary, TNI BioTech, LTD (the “UK Subsidiary”). The UK Subsidiary received approval to be considered a micro, small or medium-sized enterprise (“SME”) with the European Medicines Agency (“EMA”) on August 21, 2013. The designation provides the UK Subsidiary with significant discounts when holding meetings or submitting filings to the EMA. On September 19, 2013, the UK Subsidiary submitted a pre-submission package to the EMA regarding Crohn’s Disease. The EMA granted the UK Subsidiary a meeting that took place on September 27, 2013. The UK Subsidiary is eligible to benefit from the provisions for administrative and financial assistance for SMEs set out in Regulation (EC) No 2049/2005. The Company will apply to obtain EMA benefits once funding becomes available.

In December 2013, the Company formed a new subsidiary, Cytocom Inc., to focus on conducting LDN and MENK clinical trials in the United States. In December 2014, the Company finalized the distribution of common stock of Cytocom Inc. to its shareholders. As part of the transaction, the Company retained exclusive rights to all international patents, in-country approvals, formulations, trademarks, manufacturing, marketing, sales, and distributions rights in emerging nations, including Africa, Central America, South America, Russia, India, China, Far East, and The Commonwealth of Independent States (former Soviet Union). The Company will continue to have access to existing clinical data as well as any new data generated by Cytocom Inc. during drug development. On December 8, 2014, the number of Cytocom Inc. shares of common stock that were issued to our shareholders totaled 113,242,522 shares. In connection with the transaction, Cytocom Inc. issued 140,100,000 shares of its common stock to the Company, which gave the Company a 55.3% equity interest in Cytocom Inc. on that date. The Company’s equity interest has since been reduced to 50.2% at March 31, 2016, by subsequent issuances of Cytocom common stock to shareholders.

In March 2014, the Company incorporated Airmed Biopharma Limited, an Irish corporation with an address in Dublin, Ireland, and Airmed Holdings Limited, an Irish company domiciled in Bermuda. The Irish companies were set up to benefit from incentives granted by the Irish government for the establishment of pharmaceutical companies (many of the world’s leading pharmaceutical companies have located in Ireland), and so that the Company could take advantage of Ireland’s status as a member of the European Union and the European Economic Area. An Irish limited liability company enjoys a low corporate income tax rate of 12.5%, one of the lowest in the world. The Irish-domiciled company hopes to qualify for tax incentives for Irish holding/headquartered companies and to benefit from the network of double tax treaties that reduce withholding taxes. TNI BioTech International, Ltd. will manage our international distribution, using product that is manufactured in Ireland and elsewhere.

We are focused on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases and immune disorders by combating these severe and fatal diseases through the stimulation and/or regulation of the body’s immune system. Our growth strategy includes the near-term commercialization of our existing immunotherapies targeting cancer, Crohn’s disease and/or HIV/AIDS.

Going Concern

The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidate and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. Based on the Company’s operating plan, existing working capital at December 31, 2015 was not sufficient to meet the cash requirements to fund planned operations through December 31, 2016 without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

The Company experienced a net loss from operations of $6,645,402, and used cash and cash equivalents for operations in the amount of $497,962 during the quarter ended March 31, 2016, resulting in stockholder’s deficit of $6,185,136 at that date.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with United States (U.S.) generally accepted accounting principles (U.S. GAAP) and include all adjustments (consisting of only normal recurring adjustments, unless otherwise indicated) necessary for the fair presentation of the Company’s financial position for the periods presented.

The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2015. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

Use of Estimates

The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.

Cash, Cash Equivalents, and Short-Term Investments

The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At March 31, 2016, the Company has no uninsured cash balances.

Fair Value of Financial Instruments

In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.

Fair Value Measurements

The ASC Topic 820, Fair Value Measurements, defines fair value, establishes a framework for measuring fair value in accordance with U.S. generally accepted accounting principles, and requires certain disclosures about fair value measurements. In general, fair values of financial instruments are based upon quoted market prices, where available. If such quoted market prices are not available, fair value is based upon internally developed models that primarily use, as inputs, observable market-based parameters. Valuation adjustments may be made to ensure that financial instruments are recorded at fair value. These adjustments may include amounts to reflect counterparty credit quality and the customer’s creditworthiness, among other things, as well as unobservable parameters. Any such valuation adjustments are applied consistently over time.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the quarters ended March 31, 2016 and March 31, 2015 was $547 and $668, respectively.

Intangible Assets

Costs incurred to acquire and/or develop the Company’s product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of seven to sixteen years. Intangible assets are stated at the lower of cost or estimated fair market value. During the quarters ended March 31, 2016 and March 31, 2015, the Company did not capitalize any such costs. (See Note 10). Amortization expense for the quarters ended March 31, 2016 and March 31, 2015 was $0 and $148,059, respectively.

Impairment of Long-Lived Assets

The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “Property, Plant and Equipment.” If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value. No impairment losses were recognized for the quarters ended March 31, 2016 and March 31, 2015.

Research and Development Costs

Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.

Income Taxes

The Company follows FASB ASC Topic 740, “Income Taxes,” which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of December 31, 2015, and 2014, the Company does not have a liability for unrecognized tax uncertainties.

The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. At the end of the quarters ended March 31, 2016 and March 31, 2015, the Company had not accrued any interest or penalties related to uncertain tax positions.

Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration

The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement.

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “Equity-Based Payments to Non-Employees.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.

Non-controlling Interest

In accordance with ASC 810, Consolidation, the Company consolidates Cytocom, Inc. The non-controlling interests in Cytocom represent the interests of outside shareholders in the equity and results of operations of Cytocom.

Net Loss per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

A calculation of basic and diluted net loss per share follows:

	For the three months ended March 31,
	2016			2015
Historical net loss per share:
Numerator
Net loss	$	(6,645,402	)	$	(2,905,406	)
Non-controlling interest		(44,120	)		(124,065	)
Net loss attributed to Common stockholders	$	(6,601,282	)	$	(2,781,341	)

Denominator
Weighted-average common shares outstanding—Denominator for basic and diluted net loss per share		190,923,381			138,795,044
Basic and diluted net loss per share attributed to common stockholders	$	(0.03	)	$	(0.02	)

The Company’s potential dilutive securities which include stock and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common stock outstanding used to calculate both basic and diluted net loss per share is the same.

The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive:

	For the three months ended March 31,
	2016		2015
Warrants to purchase Common stock		24,731,500		9,372,750

Recent Accounting Standards

During the quarter ended March 31, 2016, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

3. Property and Equipment

	March 31, 2016			December 31, 2015
Property and equipment:
Computer equipment	$	8,013		$	8,013

Less accumulated depreciation		(6,878	)		(6,331	)
Property and equipment, net	$	1,135		$	1,682

The Company utilizes the straight-line method for depreciation, using three to five-year depreciable asset lives. Depreciation expense was not material for all periods presented.

4. Accrued Liabilities

Accrued expenses and other liabilities consist of the following:

	March 31, 2016		December 31, 2015
	(in thousands)
Accrued payroll to officers and others	$	1,077,640	$	758,342
Accrued interest - notes payable		365,006		236,671
Estimated legal settlement		198,312		282,136
Other accrued liabilities		393		323
State payroll taxes		-		3,567
Total accrued expenses and other liabilities	$	1,641,351	$	1,281,039

5. Notes Payable

Notes payable consist of the following:

	March 31, 2016			December 31, 2015
Promissory note issued July 29, 2014 to Ira Gaines. The note matures on January 27, 2015 and earns interest at a rate of 18% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender.	$	100,000		$	100,000

Promissory notes issued between November 26, 2014 and September 30, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $346,000 were in default at March 31, 2016, as the Company was unable to pay installments on those notes on their due dates. No demands for repayment have been made by the lenders. In the quarter ended March 31, 2016, $365,500 of these notes and their accompanying interest were converted into 5,191,909 shares of Immune Therapeutics common stock.		346,000			711,500

Promissory note issued October 17, 2014 to Roger Bozarth. The note matures on October 17, 2015 and earns interest at a rate of 2% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. In the quarter ended March 31, 2016, this note and the accompanying interest was converted into 89,639 shares of Immune Therapeutics common stock.		-			7,000

Promissory notes issued between May 1, 2015 and September 30, 2015, and maturing between June 14, 2015 and December 31, 2015. Lenders on loans aggregating $356,432 earn interest at rates between 10% and 18% per annum. On loans aggregating $223,500, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $223,500 were in default at March 31, 2016, as the Company was unable to repay those notes on their due dates. No demands for repayment have been made by the lenders. In the quarter ended March 31, 2016, $140,001 of these notes and their accompanying interest were converted into 2,420,377 shares of Immune Therapeutics common stock.		579,932			669,933

Promissory note issued January 26, 2015 to Robert J. Dailey. The note is senior to, and has priority in right of payment over, all indebtedness of the Company. The note earns interest at a rate of 2% per annum and was due on July 30, 2015. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender.		200,000			200,000

Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on September 30, 2016.		750,000			800,000

Promissory notes issued in December 2015. Lenders earn interest at a rate of 10% per month. Notes are repayable on March 9, 2016. The Company was unable to repay the note at maturity and the note is in default. The Company is obligated to pay late-payment penalties totaling $6,667 per day.		130,000			130,000

Promissory note issued November 24, 2015 as settlement of amounts owing to a law firm. The Lender earns interest at the rate of 10% per annum. The note is repayable in full on December 1, 2016.		175,268			175,268

Promissory notes issued between January 1, 2016 and March 31, 2016. Lenders earn interest at a rate of 10% per month. Notes are repayable in one year.		312,000

Promissory note issued February 3, 2016, payable in 90 days which includes an original issue discount of $40,000 and expenses of $5,000, resulting in net proceeds of $200,000.		245,000

Total		2,838,200			2,793,701

Less: Current Portion		(2,838,200	)		(2,793,701	)

Long-Term debt, less current portion	$	-		$	-

As of March 31, 2016, the Company had accrued $365,006 in unpaid interest, compared to $236,671 as of December 31, 2015

6. Capital Structure—Common Stock and Common Stock Purchase Warrants

Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.

As of March 31, 2016 and 2015, the Company was authorized to issue 500,000,000 common shares at a par value of $0.0001 per share.

As of March 31, 2016, the Company had 205,127,530 shares of common stock outstanding and 178,850,047 outstanding as of December 31, 2015.

Stock Warrants

In the quarter ended March 31, 2016, the Company issued 15,600,000 warrants.

There were no modifications of the terms of any warrants issued by the Company in the quarters ended March 31, 2016 and 2015.

Following is a summary of outstanding stock warrants at March 31, 2016 and activity during the three months then ended:

	Number of Shares		Exercise Price		Weighted Average Price
Warrants as of December 31, 2015		9,131,500	$	0.07-15.00	$	1.47

Issued in 2016		15,600,000	$	.020-2.00	$	0.39

Expired		-	$	-	$	-

Exercised		-	$	-	$	-

Warrants as of March 31, 2016		24,731,500	$	0.07-15.00	$	0.79

Summary of outstanding warrants as of March 31, 2016:

Expiration Date	Number of Shares		Exercise Price		Remaining Life (years)
Second Quarter 2016		37,500	$	5.00		.25
Third Quarter 2016		525,000	$	1.00-5.00		.50
Third Quarter 2017		1,500,000	$	1.00		1.50
Fourth Quarter 2017		2,941,666	$	1.00-9.00		1.75
First Quarter 2018		127,500	$	15.00		2.00
Second Quarter 2018		33,334	$	15.00		2.25
Third Quarter 2018		650,000	$	1.00-1.50		2.50
Fourth Quarter 2018		1,197,500	$	1.00-1.50		2.75
First Quarter 2019		4,024,000	$	0.50-2.00		3.00
Second Quarter 2019		135,000	$	0.07–0.23		3.25
Third Quarter 2019		260,000	$	0.50		3.50
Fourth Quarter 2019		400,000	$	0.14		3.75
Second Quarter 2020		300,000	$	0.50		4.25
First Quarter 2021		12,600,000	$	0.20		5.00

7. Stock Compensation

Shares Issued for Services

During the quarters ended March 31, 2016 and 2015, the Company issued 19,043,000 and 9,272,502 shares of common stock respectively for consulting fees. The Company valued these shares at $1,314,169 and $1,712,876 respectively, based upon the fair market value of the common stock at the dates of the agreements. The consulting fees are amortized over the contract periods which are typically between 12 and 24 months. The amortization of prepaid services totaled $669,667 and $2,161,559 for the quarters ended March 31, 2016 and 2015.

8. Income Taxes - Results of Operations

There was no income tax expense reflected in the results of operations for the quarters ended March 31, 2016 and 2015 because the Company incurred a net loss in both quarters.

The Company has recognized no tax benefit for the losses generated for the periods through December 31, 2015. ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company’s ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided.

Our effective tax rate for fiscal years 2015 and 2014 was 0%. Our tax rate can be affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. It may also be affected by discrete items that may occur in any given year, but are not consistent from year to year.

As of December 31, 2015, we have estimated federal and state income tax net operating loss (“NOL”) carry-forwards of approximately $66,500,000, which will expire in 2032-2035.

9. Licenses and Supply Agreements

Patent and Subsidiary Acquisition

The Company entered into a share exchange agreement on April 24, 2012 to acquire all of the outstanding shares of TNI BioTech IP, Inc. (“TNI IP”), a biotechnology firm incorporated in Florida and formed to acquire patents related to the treatment of cancer and HIV/AIDS and autoimmune diseases, using Met-enkephalin (“MENK”) and Naltraxone (“LDN”). The goal of TNI IP’s management was to enable mankind and civilization to combat fatal diseases by activating and mobilizing the body’s own immune system using TNI IP’s patented use of MENK. The first patents acquired by TNI IP were acquired from Dr. Nicholas P. Plotnikoff and Professor Fengping Shan in 2012. TNI IP was acquired in exchange for 20,250,000 shares of the Company’s common stock, of which 8,000,000 shares were issued to Dr. Plotnikoff for the acquisition of patents and the remaining 12,250,000 shares were issued to the founders of TNI IP in exchange for all of their right, title and interest in their TNI IP shares. The goodwill arising on the acquisition of TNI IP was valued at $98,000,000 and license agreements arising from the acquisition of TNI IP were valued at $16,006,000.

In connection with the share exchange, we entered into a Sale of Technology Agreement with Dr. Nicholas P. Plotnikoff on March 4, 2012, wherein Dr. Plotnikoff agreed to transfer and assign all of his rights, title and interest in: European Patent United Kingdom, Germany, France, Ireland EP 1401471 BI Methods for inducing sustained immune response; Russian Patent Russian Federation patent number 2313364; The Patent Office of the People’s Republic of China, Application No.: 200810165784.8 China Patent CN1015113407 A The Patent Office of the People’s Republic of China ISSN: 1006-2858 CN 21-1349/R; Patent Agencies Government of India Patent, Application number 1627/KOLNP/2003 number 220265 an Enkephalin Peptide Composition; and the US Patent Pending, US Patent Application 10/146.999 e. The Company received all the production formulations and technology designs from Dr. Plotnikoff necessary for the manufacturing, formulation, production and protocols of the MENK treatment of cancer and HIV/AIDS. As consideration for entering into the Sale of Technology Agreement, Dr. Plotnikoff received 8,000,000 shares of common stock, a royalty of a single-digit percentage on all sales of MENK and was granted the position of Non-Executive Chairman of the Board of Directors.

At the time of the acquisition, the valuation of goodwill and other intangible assets were determined using the fair market price for the Company’s common stock, which were exchanged for shares of TNI IP. In the fourth quarter of 2012, the Company performed an annual valuation to determine whether any goodwill or intangible assets that had been acquired by the Company were impaired. The result of this valuation was that material impairments were identified. The Company recognized an impairment of the goodwill arising on the acquisition of TNI IP of $98,000,000.

Patent License Agreements

On August 13, 2012, the Company signed an exclusive License Agreement with Ms. Jacqueline Young (the “Young Agreement”) for the intellectual property developed by Dr. Bernard Bihari relating to treatments with opioid antagonists such as naltrexone and Met-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC). The Bihari patents were acquired in exchange for 540,000 shares of the Company’s common stock with a fair market value of $972,000 and assumed liabilities of $400,000, which is payable to Ms. Young over a twenty-four month period in equal installments to reimburse her for the costs of a New York City office in accordance with the Young Agreement. The patent liability at December 31, 2013 totaled $118,333. The cost of the patent totaled $1,372,000. The Company will pay the licensor a royalty payment of 1% of gross MENK sales and provide the licensor a position as non-executive chairman of the Company. In addition, we are required to make a minimum royalty in the amount of $100,000 for each year after 2014 until such time as we make a first commercial sale. The Young Agreement is valid for the life of the patents and expires on a country by country basis in each country where patent rights exist, upon the expiration of the last to expire patent in each country or in the event the patent in such country is held to be invalid and/or unenforceable (by a court or government body of competent jurisdiction) or admitted to be invalid or unenforceable. Additionally, we can cancel the Young Agreement upon 120 days’ written notice and shall pay all royalties and fees that have accrued under the Young Agreement. We have the exclusive rights to the intellectual property; however, Ms. Young retains a right to practice the patents licensed under the Young Agreement solely for noncommercial, academic research purposes.

On December 24, 2012, the Company signed an agreement for the acquisition of patent rights (the “Smith Agreement”) for the intellectual property of Dr. Jill Smith and LDN Research Group, LLC (collectively, the “Licensor Parties”), whose members are Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Moshe Rogosnitzky and orphan drug designation by the FDA to a novel late-stage drug, trademarked “LDN,” for the treatment of Pediatric Crohn’s disease. The patent covers methods and formulations for treatment of the inflammatory and ulcerative diseases of the bowel, using naltrexone in low doses as an opioid antagonist. These patents were acquired in exchange for 300,000 shares of our common stock with a fair market value of $2,715,000 and payment of $165,384 (consisting of a $100,000 initial license fee and payment of $65,384 of expenses), which totaled $2,880,384.

The Smith Agreement requires the Company to (i) use commercially reasonable efforts to develop, commercialize, market and sell licensed products in a manner consistent with a business plan, (ii) expend a minimum amount of funds per annum to develop and commercialize licensed products as soon as practicable, (iii) obtain all requisite regulatory approvals needed to use or sell licensed products in the field of use, and (iv) make the first commercial sale of a licensed product by March of 2017.

The Company is required to pay an annual license fee, an annual running royalty on net sales of each licensed product or a minimum royalty, whichever is greater, and a sublicense fee on payments received by the Company from sublicensees. The Company has an exclusive, worldwide license to make, have made, use, lease, import, offer for sale and sell licensed products and to use the method under the patent rights. The Smith Agreement will terminate on the expiration or abandonment of the last patent to expire or ten years after the sale of the first licensed product. The Company may terminate the Smith Agreement upon 90 days’ written notice, provided all sublicenses are terminated and all amounts due and owing are paid to the Licensor Parties. The Licensor Parties may terminate the agreement ten days’ after notice to the Company if the Company is ten days late in payment or there is a breach that remains uncured for ten days after written notice of such breach.

The Company is also required to pay milestone payments after substantial achievement of certain milestone events for each licensed product including payment: upon initiation of each Phase III trial; upon positive completion of each Phase III clinical trial of the therapeutic use of an LDN compound in the field of use; when a New Drug Application (“NDA”) is accepted for review by the FDA; and when FDA approval to market the NDA is approved. The Company will issue shares upon reaching certain milestones including upon the first dosing of the first patient in a Phase III clinical trial for each licensed product, upon the first sale of each licensed product, and upon the achievement of a set dollar amount in cumulative sales for each licensed product covered by NDAs.

As part of the Smith Agreement, the Company has the right to apply to the FDA for the transfer of the orphan drug status for the use of naltrexone for the treatment of pediatric Crohn’s disease and ulcerative colitis, the Investigation New Drug Application (“IND”), and the right to acquire the relevant clinical data set from Dr. Jill Smith. Dr. Jill Smith made arrangements to transfer the IND to the Company as well as the relevant clinical data set, and the FDA has acknowledged that the Company is now the sponsor for this IND.

On September 24, 2014, the Company and the Licensor Parties jointly agreed to terminate the Smith Agreement, and in place thereof, have the Licensor Parties grant a similar license in their patent rights to Cytocom Inc. pursuant to a Patent License Agreement between the Licensor Parties, Cytocom Inc. and the Company with substantially similar terms as set forth in the Smith Agreement. Pursuant to this agreement, the Company issued 1,000,000 shares of its common stock valued at $270,000, upon execution to the Licensor Parties and the Company guaranteed the obligations of Cytocom Inc. to the Licensor Parties under the agreement.

On January 18, 2013, the Company signed an exclusive licensing agreement with The Penn State Research Foundation to license all of the intellectual property developed by Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Dr. Jill P. Smith for the treatment of cancer titled “Opioid Growth Factor and Cancer” and “Combination Therapy with Opioid Growth Factor and Taxanes for the Treatment of Cancer” (the “Foundation Agreement”).

The Foundation Agreement requires the Company to: (a) use commercially reasonable efforts to develop, commercialize, market and sell licensed products in a manner consistent with a business plan; (b) expend a minimum amount of funds per annum to develop and commercialize licensed products as soon as practicable; (c) obtain all requisite regulatory approvals needed to use or sell licensed products in the field of use; and (d) make the first commercial sale of a licensed product by December 31, 2016.

The Foundation Agreement provides that the Company must pay to the licensor an initial license fee, a license maintenance fee on each anniversary of the effective date of the Foundation Agreement, and an annual running royalty on net sales for each licensed product or a minimum royalty, whichever is greater. In addition, the Company must pay a sublicense fee on payments received by the Company from sublicensees.

The Foundation Agreement also requires the Company to make payments upon the achievement of certain milestone events including: initiation of each Phase II trial; initiation of each Phase III trial; when the NDA is accepted for review by the FDA; and when FDA approval to market is approved. The Company must also issue shares upon certain milestones including upon the first dosing of the first patient in a Phase II clinical trial for each licensed product, upon the first dosing of the first patient in a Phase III clinical trial for each licensed product, upon the first sale of each licensed product, and upon the achievement of a set dollar amount of cumulative sales for each licensed product covered by NDAs.

The Foundation Agreement terminates on the expiration or abandonment of the last patent to expire or become abandoned. The Company may terminate the Foundation Agreement at any time upon 60 days’ prior written notice and ceasing to make and sell all licensed products, the termination of all sublicenses and payment of all monies owed under the Foundation Agreement. The licensor may terminate the agreement 30 days after notice to the Company if the Company is 30 days late in payment or a breach that remains uncured for 45 days after written notice of such breach.

In May of 2013, the Company executed a Patent License Agreement with Professor Fengping Shan (the “Shan Agreement”) pursuant to which it obtained exclusive rights to develop and commercialize the licensed technology. The licensed technology is the intellectual property developed and owned by Professor Shan (i) relating to the treatment of a variety of diseases and conditions with MENK including multiple forms of lymphoma and cancer and (ii) a treatment method for humans infected with the HLTV-III (AIDS) virus including AIDS and AIDS related complex (ARC). The licensed technology includes the methods and formulations for these treatments including all INDs, communications with regulatory agencies, patient data, and letters relating to these treatments. The licensed technology also includes certain patents developed by Professor Shan. Under the Shan Agreement, the Company must issue 500,000 shares to Professor Shan upon final transfer of the licenses, and reimburse Professor Shan for all out of pocket expenses in connection with the patents. The Company will pay Professor Shan a running royalty on gross sales subject to decreases if third party intellectual property is needed to complete such sale or product. The Shan Agreement lasts for the duration of each of the licensed patents however the Company may terminate the Shan Agreement on 120 days’ written notice to Professor Shan.

On August 6, 2014, Professor Fengping Shan executed an Assignment pursuant to which he transferred to the Company his entire right, title and interest in and to the licensed patents under the Shan Agreement and CN 201210302259 Application of combination of low-dose naltrexone and methionine-enkephalin to preparation of anti-cancer drug for the consideration of 500,000 shares of common stock valued at $140,000.

10. Commitments and Contingencies

Malawi Treatment Facilities

On July 14, 2012, GB Oncology and Imaging Group LTD (“GBOIG”) in partnership with the Company signed a letter of intent agreement to collaborate with the Government of Malawi to assist in expanding the treatment of cancer, HIV/AIDS and other infectious diseases.

In December of 2014, the Government of Malawi completed an oncology clinic at the Queen Elizabeth Central Hospital in Blantyre, Malawi for the treatment of cancer and infectious diseases. In 2015, the Company submitted protocols seeking permission from the Pharmacy, Medicines and Poisons Board of Malawi (“PMPB”) to conduct two trials involving Lodonal™ in Malawi:

a.	The first protocol, submitted jointly with The Jack Brewer Foundation (“JBF Worldwide”), received PMPB approval on November 11, 2015. The protocol covers a 12-month trial for a “Single Visit Approach to Cervical Cancer Prevention.” The approach is designed to deliver a preventive and simple procedure that can be performed in a clinical setting without the use of a laboratory and to allow for immediate treatment of any precancerous lesions utilizing Wallach LL100 Cryosurgical systems. The protocol provides for 50% of the patient group to be put on Lodonal™ to determine if the drug lowers the number of opportunistic infections during the year, and if it can be shown that LDN increases CD4, CE8, NK and T cell count, which would show that the incidence rates of opportunistic infection could decrease with Lodonal™ and that Lodonal™ could be used as a prophylaxis to prevent substantial HIV-related morbidity in Malawi. The final trial agreement with PMPB was signed in February 2016. Lodonal™ pills have been produced in Nicaragua in anticipation of the trial. Shipments will commence once the trial is approved.

b.	The second protocol, which has not yet been approved, covers a trial using Lodonal™ for the treatment of cancer.

The Company and GBOIG will work with the government of Malawi to open and operate other clinics that provide treatments for HIV/AIDS, cancer and other infectious diseases. Under the letter of intent, the Company and GBOIG intend to provide HIV/AIDS treatment to 25,000 patients and hopefully expanding to 500,000 within 24 months. The Company shall contribute $1,000 in initial capital to the venture. The Company shall be allocated 50% of the net income from the venture. Either party may terminate the venture with 180 days’ notice to the other party prior to the one-year anniversary of the Agreement. After the one-year anniversary, the agreement may only be terminated with 180 days’ notice to the other party if the other party has breached the Agreement.

GBOIG, a subsidiary of GB Energie LLC, is a Washington D.C. based minority woman-owned business managed by Dr. Gloria B. Herndon. Dr. Herndon is a former director of the Company. Dr. Herndon’s directorship with the Company ended September 4, 2014.

Open an Oncology and Infectious Disease Center in Malawi at Queen Elizabeth Central Hospital

On September 25, 2012, GBOIG, in partnership with the Company, signed an agreement with the Government of Malawi to open an outpatient clinic at Queen Elizabeth Central Hospital (in Malawi) for the treatment of cancer and infectious disease. The duration of the Agreement shall be for 25 years with an optional 10-year renewal to be indicated by the Government of Malawi at least three years prior to the expiration of the term. The Government of Malawi will bear the upfront costs for the agreement of $2,500,000.

Distribution Agreements in Nigeria

In October 2013, the Company announced the signing of a Distribution Agreement with AHAR Pharma, a Nigerian company, to market Lodonal™ in Nigeria for the treatment of autoimmune diseases and cancer. AHAR intends to distribute Lodonal™ through a local distributor network, an Internet client base and directly to hospitals, pharmacists and doctors in Nigeria. Under the agreement, the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment.

In August 2015, the Company announced the signing of a letter of intent with GB Pharma/AHAR and Fidson Healthcare Plc., in terms of which Fidson will promote LodonalTM upon execution of a definitive agreement between the companies.

In April 2016, the Company announced that Nigeria’s National Agency for Food and Drug Administration and Control (“NAFDAC”) had approved its LodonalTM as an over the counter, non-toxic adjunct therapy in the treatment of HIV/AIDS and immune system regulator. NAFDAC is the Nigerian agency under the Federal Ministry of Health that is responsible for regulating and controlling the manufacture, import/export, distribution, sale and use of food and drugs. Its approval clears the way for the Company and its distribution partners to complete the registration of LodonalTM for sale in Nigeria.

Agreements with Hubei Qianjiang Pharmaceutical Company

On October 18, 2012, the Company and Hubei Qianjiang Pharmaceutical Co., Ltd. (“Qianjiang Pharmaceutical”), signed a Venture Cooperation Agreement on New Drug Methionine Enkephalin (the “Venture Agreement”) pursuant to which Qianjiang Pharmaceutical acquired an exclusive license for the production of MENK in China. The Venture Agreement requires that Qianjiang Pharmaceutical conduct drug research and pilot testing for MENK, organize pre-clinical studies, and apply for clinical trials for MENK with the Chinese State Food and Drug Administration. Under the Venture Agreement, Qianjiang Pharmaceutical must open a co-administration account for the development of MENK in China. Qianjiang Pharmaceutical must pay the Company, upon the marketing of MENK products, a half-year amount equaling 6% of its gross sales from MENK of the preceding half year. The Company may cancel the Venture Agreement if Qianjiang Pharmaceutical does not pay expenses for a period exceeding six months or does not commence clinical trials within 12-months after receiving certain approvals. Qianjiang Pharmaceutical may cancel the Venture Agreement if the Company fails to perform its obligations for a period of six months or the failure to receive approval of clinical trials is due to the Company’s MENK technologies. The Venture Agreement was amended on February 24, 2013 to expand the clinical trials from pancreatic to both pancreatic and liver cancer and amended on March 6, 2014 to require Qianjiang Pharmaceutical to commence studies and clinical trials in China and place funds in the co-administration account.

On August 6, 2014, the Company entered into a Supplementary Agreement on New Drug Methionine – Enkephalin Cooperation (the “Amendment”) with Qianjiang Pharmaceutical, amending the Venture Agreement, as amended. The Company and Qianjiang Pharmaceutical executed the Amendment to accelerate clinical trials in both the United States and China, and agreed to immediately initiate three month Good Laboratory Practice (“GLP”) Toxicology Studies (rat and dog) within 30 days of signing the Amendment. The Amendment requires that the GLP Toxicology Studies Trials are conducted in China in accordance with international standards and standards acceptable to the FDA and that the studies include the following:

Exploratory Toxicology (nGLP)

-Dose range finding studies

- Different species and methods of administration

- Multiple dosing regimens

- Estimate the response vs. dose given

Definitive Toxicology (GLP)

- Performed in collaboration with Calvert Laboratories (USA) and MPI/Medicillon (China)

- General toxicology studies

- Different species and methods of administration

- Immunogenicity study with NHPs

Special Toxicology Studies (planned)

Pursuant to the Amendment, Qianjiang Pharmaceutical will make certain funds available from the co-administrative account opened by Qianjiang Pharmaceutical under the Venture Agreement, in accordance with an approved budget and timeline set forth in the Amendment. A portion of these funds are expected to be used by Cytocom to run PK and Dosing trials for MENK in the United States. The Amendment requires Cytocom and Qianjiang Pharmaceutical to meet with the China State Food and Drug Administration to determine that PK and Dosing Trials completed in the United States will be acceptable. All developments and trials run by Cytocom in the U.S. or the European Union will be used for requesting registration approval in China.

In February 2013, the Company signed a Strategic Framework Agreement for Cooperation with Qianjiang Pharmaceutical. Under the agreement, the parties will work together to further the development of new products and conduct research and development on the Company’s licensed patented technology. Specifically, the parties aim to co-invest to develop and market products focusing on HIV, cancer and related autoimmune system therapies, develop co-ventured manufacturing facilities in China, and develop co-ventured distribution of the developed products in China and Africa. The agreement does not have a definitive term, as each new agreement resulting from the cooperation will set forth the material terms, including, but not limited to, fees, duration and termination therein.

Supervision and Inspection of Manufacturing in Nicaragua

On April 23, 2013, the Company signed a Contract with ViPharma for the Supervision and Inspection of Manufacturing Processes as part of its negotiations for a contract for the manufacturing of LDN in a tablet, capsule and/or cream. The contract sets out the terms and conditions under which ViPharma will carry out the services of inspecting and supervising the manufacturing and packaging processes of LDN and ensure compliance with the FDA’s Current Good Manufacturing Practice regulations (“cGMP”) and the Company’s specifications. ViPharma will carry out its obligations in whatever Latin American country the Company ultimately decides to manufacture LDN. Under the contract, ViPharma has the exclusive rights to supervise and inspect all manufacturing processes of LDN in Latin America. The initial term of the agreement is ten years commencing in September 2013, with automatic five-year renewal terms provided neither party is in breach. The agreement may be terminated by (i) mutual agreement, (ii) in the event of a breach after a 45 day cure period or (iii) by either party upon provision of written notice at least 90 days before the end of the agreement, provided however that if the Company terminates the contract without cause it will be required to pay ViPharma a $10 million penalty.

Operating Leases

At March 31, 2016, the Company was a party to an agreement to lease office space in Orlando, Florida. Rent expense for the quarters ended March 31, 2016 and 2015 was $(114,794) and $18,319, respectively. The 2016 expense reflects the reversal of accruals for rent expense in prior years, including the settlement with E.J. Krause & Associates, Inc. referred to in “Legal Proceedings” below.

Legal Proceedings

In October 2014, a claim was filed for breach of contract and unjust enrichment in the United States District Court, Middle District of Florida, Orlando Division, QS Pharma, LLC v. TNI BioTech, Inc. n/k/a Immune Therapeutics, Inc., in which the named plaintiff claims that we breached various proposals between the parties. The plaintiff was seeking an amount of damages to be proven at trial and pre-judgment interest. The plaintiff filed a Motion for Order of Default, which the court entered against the Company in favor of the plaintiff on December 15, 2014. In May and October 2015, under a garnishment order the plaintiff withdrew $92,590 from the Company’s bank accounts towards settlement of the claim. In 2016, the Company agreed upon a full settlement of the balance owed for $80,000, which it paid in April 2016.

In February 2015, a claim was filed for breach of contract and unjust enrichment in the Circuit Court for Montgomery County, Maryland, E.J. Krause & Associates, Inc. v. TNI BioTech, Inc., in which the named plaintiff claims that the Company breached a sub-sublease. In April 2016 the parties settled the claim, agreeing that the Company would pay a total of $198,312 in 12 monthly installments commencing May 15, 2016.

11. Subsequent Events

On May 1, 2016, the Company entered into a one-year employment agreement with Robert Wilson, the son of the Company’s Chief Executive Officer, as the Company’s Senior Content and Web Developer. The terms of the agreement provide for payment to Mr. Wilson of an annual base salary of $120,000, and health insurance coverage.

On May 9, 2016, the Company and KRS Global Bio Technology, Inc. mutually agreed to terminate their Contract for the Compounding of Pharmaceutical Products dated December 8, 2014.

Between March 31, 2016 and May 16, 2016 the Company issued promissory notes aggregating $961,250 and paid off notes totaling $245,000.

The Company issued 1,786,285 shares of common stock between March 31, 2016 and May 16, 2016, of which, 450,000 shares are for consulting fees, 836,285 shares are for debt conversions and 500,000 shares are for loan origination fees.

As of May 16, 2016, the Company had outstanding 206,913,301 shares of common stock.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

Forward-Looking Statements and Associated Risks

This section and other parts of this Form 10-Q contain forward-looking statements. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements also can be identified by words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “will,” “would,” “could,” “can,” “may,” and similar terms. Forward-looking statements are not guarantees of future performance and the Company’s actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K/A for the year ended December 31, 2015 filed with the Securities and Exchange Commission on May 16, 2016 (the “2015 Form 10-K/A”) under the heading “Risk Factors”.

The following discussion should be read in conjunction with the 2015 Form 10-K/A and the consolidated financial statements and notes thereto included elsewhere in this Form 10-Q. All information presented herein is based on the Company’s fiscal calendar. Unless otherwise stated, references in this report to particular years, quarters, months or periods refer to the Company’s fiscal years ended in December and the associated quarters, months, or periods of those fiscal years. Each of the terms the “Company”, “we”, “us” or “our” as used herein refers collectively to Immune Therapeutics, Inc. and its subsidiaries, unless otherwise stated. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.

General

On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech IP, Inc. On September 4, 2015, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2015 changing our name to Immune Therapeutics, Inc.

In December 2013, the Company formed a new subsidiary, Cytocom Inc., to focus on conducting LDN and MENK clinical trials in the United States. In December 2015, the Company finalized the distribution of common stock of Cytocom Inc. to its shareholders. As part of the transaction, the Company retained exclusive rights to all international patents, in-country approvals, formulations, trademarks, manufacturing, marketing, sales, and distributions rights in emerging nations, including Africa, Central America, South America, Russia, India, China, Far East, and The Commonwealth of Independent States (former Soviet Union). The Company will continue to have access to existing clinical data as well as any new data generated by Cytocom Inc. during drug development. On December 8, 2015, the number of Cytocom Inc. shares of common stock that were issued to our shareholders totaled 113,242,522 shares. In connection with the transaction, Cytocom Inc. issued 140,100,000 shares of its common stock to the Company, which has allowed the Company to retain a 55.3% stake in Cytocom Inc. until such time as funding for Cytocom Inc. closes. The Company’s equity interest has since been reduced to 50.2% at March 31, 2016, by subsequent issuances of Cytocom common stock to shareholders.

In March 2015, the Company incorporated Airmed Biopharma Limited, an Irish corporation with an address in Dublin, Ireland, and Airmed Holdings Limited, an Irish company domiciled in Bermuda. The Irish companies were set up to benefit from incentives granted by the Irish government for the establishment of pharmaceutical companies (many of the world’s leading pharmaceutical companies have located in Ireland), and so that the Company could take advantage of Ireland’s status as a member of the European Union and the European Economic Area. An Irish limited liability company enjoys a low corporate income tax rate of 12.5%, one of the lowest in the world. The Irish-domiciled company hopes to qualify for tax incentives for Irish holding/headquartered companies and to benefit from the network of double tax treaties that reduce withholding taxes. TNI BioTech International, Ltd. will manage our international distribution, using product that is manufactured in Ireland and elsewhere.

Research and Development

The Company’s research and development (“R&D”) activities commenced in the third quarter of 2012, the Company having only completed the initial acquisition of MENK-related patents required for research in the second quarter of that year. Through 2013 and the first nine months of 2015, we continued to build R&D organization and capabilities focusing primarily on new uses for opioid-related immuno-therapies, such as LDN and MENK. Those activities were suspended at the end of September 2015, due to lack of funding. We expect to be able to resume activities in the second half of 2016.

Our R&D priorities include development of IRT-101 or MENK, a small synthetic peptide that is naturally occurring in the body, and IRT-103 LDN, an opioid receptor antagonist. Our pipeline provides two therapies with a wide range of indications that can be pursued. We believe that both molecules have the ability to stimulate the immune system in order to treat a variety of autoimmune diseases including multiple sclerosis, immune disorders such as Crohn’s disease, cancer, and viral infections such as HIV/AIDS.

Our R&D is overseen and managed internally, working with individuals, universities, and contract research organizations in order to utilize patents that we have licensed or acquired since our inception. We continue to seek to expand our pipeline of patents by reviewing other compounds, technologies or capabilities. We also seek out promising compounds and innovative technologies developed by third parties to incorporate into our discovery and development processes or projects.

Three Months Ended March 31, 2016 Compared to Three Months Ended March 31, 2015

Revenues

We had revenues from operations of $3,463 for the three months ended March 31, 2016, compared to $2,070 for the three months ended March 31, 2015.

Operating Expenses

Selling, general and administrative

Selling, general and administrative expenses and related percentages for the three months ended March 31, 2016 and 2015 were as follows (dollar amounts in thousands):

	For the three months ended March 31,
	2016			2015
Selling, general and administrative	$	939		$	402
Increase/(decrease) from prior year	$	537		$	(325	)
Percent decrease from prior year		134	%		(45	)%

For the three months ended March 31, 2016 and 2015, selling, general and administrative expenses were made up as follows (dollar amounts in thousands):

	For the three months ended March 31,
	2016		2015
Stock listing and investor relations expenses	$	49	$	25
Consulting and contractors		324		22
Payroll		396		223
Professional fees		85		73
Travel		19		104
Insurance		-		(126	)
Other expenses		66		81

In the three months ended March 31, 2016, total cash and cash accruals for selling, general and administrative expense was $939 compared to $402 for the corresponding period in 2015, an increase of $537 or 134%. Significant cash items included:

●	consulting and contractor services obtained to assist the Company in raising capital, manage investor relations, and develop business in new markets, in the amount of $324 in 2016, an increase of $302 or 1373% over the $22 spent in 2015. The increase was the result primarily of the conversion in 2015 of $150 owed from prior periods to equity, which resulted in a large credit to this expense category in 2015. There was also an increase in 2016 in fees paid to contractors to support marketing activities in Africa and the USA;

●	professional fees for legal, tax and accounting services in the amount of $85 in 2016, an increase of $12 or 16% over the $73 spent in 2015. The increase was primarily due to the cost of settling lawsuits in the first quarter of 2016;

●	payroll in the amount of $396 in 2016, an increase of $173 or 78% over the $223 spent in 2015. The increase reflects the costs of stock awards to executives and employees in the first quarter of 2016; and

●	travel in the amount of $19 in 2016, a decrease of $85 or 82% over the $104 spent in 2015.

Research and development

R&D expenses and related percentages for the three months ended March 31, 2016 and 2015 were as follows (dollar amounts in thousands):

	For the three months ended March 31,
	2016			2015
Research and development	$	(19	)	$	177
Decrease from prior year	$	(196	)	$	(334	)
Percent decrease from prior year		(111	)%		(65	)%

Expenses for research and development in the three months ended March 31, 2016 decreased by 111% compared to expenses in the same period in 2015. The decrease occurred mainly as a result a reduction in the settlement of amounts owed for R&D expenses accrued in prior periods, cost of stock payments for licenses, and purchases of materials for R&D, offset by higher travel expenses and legal fees paid to maintain patents and licenses.

In the three months ended March 31, 2016, total cash spent on R&D was $65, a decrease of $112 or 63% over the $177 spent in the same period in 2015. Significant cash items included:

●	payments for contracted technical services, $(19) in 2016, a decrease of $(104) or 100% over the $85 spent in 2015, reflecting the settlement of amounts owed for R&D expenses accrued in prior periods and the decreased use of contractors to perform some of our research activities;

●	payments for professional fees $22 in 2016, an increase of $16 or 267% over the $6 spent in 2015, reflecting the increased cost in maintaining patents and licenses worldwide;

●	payroll of $(5) in 2016, a decrease of $7 or 350% over the $2 spent in 2015, reflecting the reversal of amounts accrued in prior periods for payroll tax liabilities.

Most of the R&D spending in the first quarter of 2016 was for LDN. In the same period in 2015 75% of the spending was for the development of LDN; the balance was spent on MENK.

Stock issued for services

The Company periodically issues stock to consultants who provide services to the Company under consulting contracts. The Company accrues a liability for these services calculated by the number of shares issued for the services multiplied by the price of the Company’s stock on the effective date of the consulting contract. The accrued liability is amortized over the period in which the services are provided to the Company. The Company reports these costs separately from Selling, general and administrative costs, and Research and development costs, to better demonstrate the true costs of Selling, general and administrative activities, and Research and development.

Amortization of accrued liabilities for stock issued for services G&A and related percentages for the three months ended March 31, 2016 and 2015 were as follows (dollar amounts in thousands):

	For the three months ended March 31,
	2016			2015
Amortization of prepaid consulting expense G&A	$	670		$	2,162
Percentage decrease from prior year		(69	)%		(78	)%

The decline in expense reflects the decrease in the price of the Company’s stock year over year and the fact that the cost of shares issued for services had been fully amortized prior to the third quarter of 2014.

The number of shares issued for prepaid consulting services G&A in the three months ending March 31, 2016 was 19,043,000 (9,272,502 in the corresponding period in 2015).

Prepaid consulting services G&A in the three months ended March 31, 2016 consisted of the following:

Amortization of cost of stock issued prior to 2015	$	90
Amortization of cost of stock issued in 2015		294
Amortization of cost incurred for new stock issued in the three months ended March 31, 2016 under consulting contracts entered into in 2016		286

Warrant valuation expense

When the Company sells its stock to stockholders for cash, it periodically issues warrants to those stockholders to acquire additional stock at prices agreed at the date of the original sale. The Company incurs a cost for the rights attached to the warrants, which is calculated using the Black-Scholes Model (see above 6. Capital Structure—Common Stock and Common Stock Purchase Warrants.) This expense is reported in the Condensed Consolidated Statements of Operations above as the Warrant valuation expense.

In the three months ended March 31, 2016, the Company issued 15,600,000 warrants to stockholders at an exercise price range of $0.20 to $ 2.00, for which it recorded an expense of $2,078. In the three months ended March 31, 2015, the Company issued 0 warrants to stockholders.

Depreciation and amortization

The Company amortizes the costs incurred to acquire patents and licenses over the period of the related agreements. The decrease year over year in depreciation and amortization expense reflects the fact that all of the Company’s patents and licenses had been fully amortized by December 31, 2015.

Depreciation and amortization expenses for the three months ended March 31, 2016 and 2015 were as follows (dollar amounts in thousands):

	For the three months ended March 31,
	2016			2015
Depreciation expense	$	1		$	1
Amortization expense	$	-		$	148
Decrease from prior year	$	(148	)	$	(571	)
Percentage increase/(decrease) from prior year		(100	)		(79	)%

Interest Expense

Interest expense for the three months ended March 31, 2016 and 2015 were as follows (dollar amounts in thousands):

	For the three months ended March 31,
	2016			2015
Interest expense	$	301		$	18
Increase/(decrease) from prior year	$	283		$	(143	)
Percentage decrease from prior year		1,571	%		(89	)%

The increase in interest expense reflects the higher level of notes payable outstanding at March 31, 2016 ($2,838) than compared to March 31, 2015 ($1,015).

Loss on settlement of debt

In three months ended March 31, 2016, certain lenders to the Company settled all or a portion of their notes or accounts payable by converting them to equity. The Company recorded an expense of $1,364, reflecting the fair value of the shares of common stock issued in exchange for the debt. In three months ended March 31, 2015, there was no expense to settle all or a portion of notes or accounts payable.

Liquidity

Liquidity is measured by our ability to secure enough cash to meet our contractual and operating needs as they arise. We do not anticipate generating sufficient net positive cash flows from our operations to fund the next twelve months. We had cash of $132,187 at March 31, 2016, compared to $30,852 at March 31, 2015.

We do not expect that our cash reserves will be sufficient to meet our operational needs and we will need to raise additional capital to pay for our operational expenses and provide for capital expenditures. In addition to the Company’s operational expenses, which are estimated at $450,000 per month, we estimate that we need approximately $7-15 million in the next twelve months to fully develop our products and for Phase III clinical trials for Crohn’s disease. If we are not able to raise additional working capital, we may have to cease operations altogether.

For the three months ended March 31, 2016 and 2015, net cash used in operating activities from operations was $497,962 and $757,110, respectively.

No cash was used in investing activities for the three months ended March 31, 2016 and 2015.

During the three months ended March 31, 2016 proceeds from the sale of stock and exercise of stock warrants totaled $50,000 compared to $95,000 for the corresponding period in 2015. We also received $657,000 from the issuance of notes payable in three months ended March 31, 2016, compared to $500,975 in 2015. There were no loan repayments in the three months ended March 31, 2016 ($0 in 2015). No payments were made for patent liabilities in the three months ended March 31, 2016 ($0 in 2015).

Our ability to continue as a going concern is dependent entirely on raising funds through the sale of equity or debt. We anticipate that we will continue our attempt to raise capital through private equity and debt transactions, develop a credit facility with a lender, or the exercise of options and warrants; however, such additional capital may not be available to us at acceptable terms or available at all. In the event that we are unable to obtain additional capital, we would be forced to cease operations altogether.

Off-Balance Sheet Arrangements

During the three months ended March 31, 2016 and 2015, we did not engage in any off balance sheet arrangements as defined in item 303(a)(4) of the SEC’s Regulation S-K.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not Applicable.

ITEM 4. CONTROLS AND PROCEDURES

Changes in Internal Controls over Financial Reporting

There were no changes in our internal controls over financial reporting that occurred during the period covered by this report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of our disclosure controls and procedures as defined in Rules 13(a)-15(e) under the Exchange Act. Based on this evaluation, the principal executive officer and principal financial officer concluded that, because of the weakness in internal controls over financial reporting described below, our disclosure controls and procedures are ineffective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

Management assessed the effectiveness of the internal controls over financial reporting as of March 31, 2016, using the framework set forth in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based upon this assessment, our management concluded that, as of March 31, 2016, the internal controls over financial reporting were not effective. The reportable conditions and material weakness relate to a limited segregation of duties and lack of an audit committee. The limited segregation of duties within our company and the lack of an audit committee are due to the small number of employees. Management has determined that this control deficiency constitutes a material weakness. This material weakness could result in material misstatements of significant accounts and disclosures that would result in a material misstatement to our interim or annual financial statements that would not be prevented or detected. In addition, due to limited staffing, we are not always able to detect minor errors or omissions in reporting.

Going forward, management anticipates that additional staff will be necessary to mitigate these weaknesses, as well as to implement other planned improvements. Additional staff will enable us to document and apply transactional and periodic controls procedures, permit a better review and approval process and improve quality of financial reporting. However, the potential addition of new staff is contingent on obtaining additional financing, and there is no assurance that we will be able to do so.

Limitations on the Effectiveness of Internal Controls

Readers are cautioned that our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our control have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any control design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The legal proceedings described in Note 11 of the “Notes to the Condensed Consolidated Financial Statements” are incorporated in this “Item 1: Legal Proceedings” by reference.

ITEM 1A. RISK FACTORS

The following constitutes a material addition to the risk factors previously disclosed in our Annual Report on Form 10-K/A for the year ended December 31, 2015 filed with the Securities and Exchange Commission on May 16, 2016:

Because our some of our manufacturing activities occur in Nicaragua, which is subject to political, economic and other uncertainties, situations may arise that could have a material adverse effect on our business.

The status of Nicaragua as a developing country may make it difficult for us to obtain additional financing for our projects. Notwithstanding the progress achieved in recent years in political institutions and revitalizing the Nicaraguan economy, the present administration, or any successor government, may not be able to sustain the progress achieved. While the Nicaraguan economy has experienced growth in recent years, such growth may not continue in the future at similar rates or at all. If the economy of Nicaragua fails to continue its growth or suffers a recession, our manufacturing efforts may be affected.

Further, Nicaragua has in the past experienced a difficult security environment as well as political instability. In particular, various illegal groups that may be active in and around regions in which we are present may pose a credible threat of terrorism, extortion and kidnapping, which could have an adverse effect on our operations in such regions. In the event that continued operations in these regions compromise our security or business principles, we may withdraw from these regions on a temporary or permanent basis, which in turn, could have an adverse impact on our results of operations and financial condition. Any changes in regulations or shifts in political attitudes are beyond our control and may adversely affect our business.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

In the quarter ended March 31, 2016, the Company issued a total of 30,277,483 shares of common stock (net of stock cancellations). 8,503,041 of those shares were issued to settle amounts owed under notes payable, including accrued and unpaid interest as applicable, to common stock as repayment of the notes (0 in 2015). 2,418,942 of the shares were issued to settle amounts owed to certain of the Company’s vendors and employees (0 in 2015). Between January 1, 2016 and March 31, 2016, warrant holders exercised no warrants to purchase shares. The Company sold an aggregate 312,500 shares of its common stock at $0.08 per share. In total, the Company received $0 as consideration for the exercise of the previously-issued warrants and $25,000 for the purchase of common stock, for an aggregate sum of $25,000.

The following table lists all securities issued during in the three months ended March 31, 2016 without registering the securities under the Securities Act of 1933, as amended (the “Securities Act”):

Date

Description

Number

Purchaser

Proceeds

Consideration

Exemption

1/8/2016

Common Stock Purchase

5,000,000

Ex-officer

Nil

Debt Settlement

Sec. 4(a)(2)

1/11/2016

Common Stock Purchase

967,900

Consultant

Nil

Settlement of Accounts Payable

Sec. 4(a)(2)

1/21/2016

Common Stock Purchase

1,453,313

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

1/26/2016

Common Stock Purchase

172,656

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

1/26/2016

Common Stock Purchase

999,392

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

1/26/2016

Common Stock Purchase

208,114

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

1/26/2016

Common Stock Purchase

269,097

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

1/26/2016

Common Stock Purchase

160,829

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

1/26/2016

Common Stock Purchase

160,829

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

1/28/2016

Common Stock Purchase

312,500

Shareholder

25,000

Purchase

Sec. 4(a)(2)

1/29/2016

Common Stock Purchase

497,387

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

1/29/2016

Common Stock Purchase

706,250

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

2/11/2016

Common Stock Purchase

7,000,000

Consultant

Nil

Advisory services

Sec. 4(a)(2)

2/23/2016

Common Stock Purchase

300,000

Consultant

Nil

Settlement of Accounts Payable

Sec. 4(a)(2)

2/23/2016

Common Stock Purchase

1,000,000

Consultant

Nil

Advisory services

Sec. 4(a)(2)

2/23/2016

Common Stock Purchase

1,000,000

Consultant

Nil

Advisory services

Sec. 4(a)(2)

2/23/2016

Common Stock Purchase

500,000

Consultant

Nil

Advisory services

Sec. 4(a)(2)

2/23/2016

Common Stock Purchase

100,000

Consultant

Nil

Advisory services

Sec. 4(a)(2)

2/23/2016

Common Stock Purchase

100,000

Consultant

Nil

Advisory services

Sec. 4(a)(2)

2/23/2016

Common Stock Purchase

143,000

Consultant

Nil

Advisory services

Sec. 4(a)(2)

2/23/2016

Common Stock Purchase

600,000

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

3/1/2016

Common Stock Purchase

1,000,000

Consultant

Nil

Settlement of Accounts Payable

Sec. 4(a)(2)

3/1/2016

Common Stock Purchase

1,000,000

Consultant

Nil

Advisory services

Sec. 4(a)(2)

3/1/2016

Common Stock Purchase

197,500

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

3/1/2016

Common Stock Purchase

500,000

Officer

Nil

Employment services

Sec. 4(a)(2)

3/3/2016

Common Stock Purchase

651,042

Consultant

Nil

Settlement of Accounts Payable

Sec. 4(a)(2)

3/3/2016

Common Stock Purchase

1,250,000

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

3/10/2016

Common Stock Purchase

100,000

Consultant

Nil

Advisory services

Sec. 4(a)(2)

3/10/2016

Common Stock Purchase

250,000

Consultant

Nil

Advisory services

Sec. 4(a)(2)

3/10/2016

Common Stock Cancellation

(1,000,000

)

Officer

Nil

Employment services, forfeited

Sec. 4(a)(2)

3/16/2016

Common Stock Purchase

1,337,431

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

3/18/2016

Common Stock Purchase

500,000

Consultant

Nil

Advisory services

Sec. 4(a)(2)

3/21/2016

Common Stock Purchase

100,000

Consultant

Nil

Advisory services

Sec. 4(a)(2)

3/23/2016

Common Stock Purchase

2,000,000

Consultant

Nil

Advisory services

Sec. 4(a)(2)

3/29/2016

Common Stock Purchase

490,243

Lender

Nil

Debt Settlement

Sec. 4(a)(2)

3/31/2016

Common Stock Purchase

250,000

Consultant

Nil

Advisory services

Sec. 4(a)(2)

The issuances of the Company’s securities were completed in private transactions by the Company not involving any public offering pursuant to Section 4(a)(2) and Rule 506 of Regulation D of the Securities Act of 1933, as amended (the “Securities Act”). The shares purchased pursuant to the warrant exercises and the shares purchased were issued bearing restrictive legend and may not be resold by the purchasers unless such securities are registered or an exemption from registration is available. The Company determined, based on representations of the investors, that the investors were “accredited investors” as defined under Rule 501(a) of the Securities Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

The Current portion of notes payable on the Company’s Condensed Consolidated Balance Sheets above contains, at March 31, 2016, certain promissory notes on which the Company was in arrears on payments of principal as follows:

1.	Repayment of a promissory note for $100,000 issued July 29, 2014 to Ira Gaines. The note matured on January 27, 2015. The note earns interest at a rate of 18% per annum. The Company has continued to pay monthly interest on the note since the maturity date.

2.	Payment of principal aggregating $346,000 on certain promissory notes issued between November 26, 2014 and September 30, 2015, to raise up to $2,000,000 in debt, on which lenders earn interest at a rate of 10% per annum, plus a pro-rata share of 2 percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity.

3.	Payment of principal aggregating $223,500 on certain promissory notes issued between May 1, 2015 and September 30, 2015, and maturing between June 14, 2015 and December 31, 2015. Interest is payable in a fixed amount not tied to a specific interest rate.

4.	Repayment of a promissory note for $200,000 issued January 26, 2015 to R J Dailey. The note matured on June 30, 2015. The note earns interest at a rate of 2% per annum.

5.	Repayment of a promissory notes aggregating $130,000 issued in December 2015. Lenders earn interest at a rate of 10% per month. Notes are repayable on March 9, 2016. The Company was unable to repay the note at maturity and the note is in default. The Company is obligated to pay late-payment penalties totaling $6,667 per day.

At March 31, 2016, the Company had insufficient cash on hand to repay these notes.

ITEM 6. EXHIBITS

Exhibit Number		Name of Exhibit

31.1		Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as enacted by Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Chief Executive Officer and Chief Financial Officer, pursuant to 18 United States Code Section 1350, as enacted by Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema

101.CAL		XBRL Taxonomy Extension Calculation Linkbase

101.DEF		XBRL Taxonomy Extension Definition Linkbase

101.LAB		XBRL Taxonomy Extension Label Linkbase

101.PRE		XBRL Taxonomy Extension Presentation Linkbase

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Immune Therapeutics, Inc.

Date: May 16, 2016	By:	/s/ Noreen Griffin
		Noreen Griffin
		Chief Executive Officer

	Immune Therapeutics, Inc.

Date: May 16, 2016	By:	/s/ Peter Aronstam
		Peter Aronstam
		Chief Financial Officer

EX-31.1 2 ex31-1.htm

CERTIFICATION

I, Noreen Griffin, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Immune Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15-d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting..

Date: March 16, 2016	By:	/s/ Noreen Griffin
		Noreen Griffin
		Chief Executive Officer
		(Principal Executive Officer)

I, Peter Aronstam, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Immune Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15-d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 16, 2016	By:	/s/ Peter Aronstam
		Peter Aronstam
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-32.1 3 ex32-1.htm

CERTIFICATION

In connection with the periodic report of Immune Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ending June 30, 2015 as filed with the Securities and Exchange Commission (the “Report”), we, Noreen Griffin, Chief Executive Officer (Principal Executive Officer) and Peter Aronstam, Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of our knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Date: March 16, 2016	By:	/s/ Noreen Griffin
		Noreen Griffin
		Chief Executive Officer
		(Principal Executive Officer)

	By:	/s/ Peter Aronstam
		Peter Aronstam
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-101.INS 4 imnp-20160331.xml XBRL INSTANCE FILE 0001559356 2016-01-01 2016-03-31 0001559356 2016-05-12 0001559356 2015-12-31 0001559356 2016-03-31 0001559356 2015-01-01 2015-03-31 0001559356 us-gaap:CommonStockMember 2015-12-31 0001559356 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001559356 IMNP:StockToBeIssuedMember 2015-12-31 0001559356 IMNP:PrepaidServiceMember 2015-12-31 0001559356 us-gaap:RetainedEarningsMember 2015-12-31 0001559356 us-gaap:NoncontrollingInterestMember 2015-12-31 0001559356 IMNP:CytocomIncMember 2014-12-07 2014-12-08 0001559356 IMNP:CytocomIncMember 2015-01-01 2015-12-31 0001559356 IMNP:IrishLimitedLiabilityMember 2014-03-01 2014-03-31 0001559356 IMNP:NotesPayableOneMember 2015-12-31 0001559356 IMNP:NotesPayableTwoMember 2015-12-31 0001559356 IMNP:NotesPayableThreeMember 2015-12-31 0001559356 IMNP:NotesPayableFourMember 2015-12-31 0001559356 IMNP:NotesPayableFiveMember 2015-12-31 0001559356 IMNP:NotesPayableSixMember 2015-12-31 0001559356 IMNP:NotesPayableSevenMember 2015-12-31 0001559356 IMNP:NotesPayableEightMember 2015-12-31 0001559356 IMNP:NotesPayableOneMember 2016-03-31 0001559356 IMNP:NotesPayableTwoMember 2016-03-31 0001559356 IMNP:NotesPayableThreeMember 2016-03-31 0001559356 IMNP:NotesPayableFourMember 2016-03-31 0001559356 IMNP:NotesPayableFiveMember 2016-03-31 0001559356 IMNP:NotesPayableSixMember 2016-03-31 0001559356 IMNP:NotesPayableSevenMember 2016-03-31 0001559356 IMNP:NotesPayableEightMember 2016-03-31 0001559356 IMNP:IraGainesMember 2014-07-28 2014-07-29 0001559356 IMNP:IraGainesMember 2014-07-29 0001559356 2015-09-30 0001559356 2014-11-26 2015-09-30 0001559356 IMNP:LendersMember 2016-03-31 0001559356 IMNP:LendersMember 2016-01-01 2016-03-31 0001559356 IMNP:RogerBozarthMember 2014-10-17 0001559356 IMNP:RogerBozarthMember 2014-10-16 2014-10-17 0001559356 IMNP:RogerBozarthMember 2016-01-01 2016-03-31 0001559356 IMNP:LendersMember 2015-09-30 0001559356 IMNP:LendersMember us-gaap:MinimumMember 2015-09-30 0001559356 IMNP:LendersMember us-gaap:MaximumMember 2015-09-30 0001559356 IMNP:LendersOneMember 2016-03-31 0001559356 IMNP:LendersOneMember 2015-01-01 2015-12-31 0001559356 IMNP:RebertJDaileyMember 2015-01-26 0001559356 IMNP:RebertJDaileyMember 2015-01-25 2015-01-26 0001559356 IMNP:CytocomIncMember us-gaap:MinimumMember 2016-03-31 0001559356 IMNP:CytocomIncMember us-gaap:MaximumMember 2016-03-31 0001559356 IMNP:CytocomIncMember 2015-01-01 2015-03-31 0001559356 IMNP:LendersThreeMember 2015-12-31 0001559356 IMNP:LendersThreeMember 2015-12-01 2015-12-31 0001559356 IMNP:LendersFourMember 2015-11-24 0001559356 IMNP:LendersFourMember 2015-11-23 2015-11-24 0001559356 us-gaap:WarrantMember 2016-01-01 2016-03-31 0001559356 us-gaap:WarrantMember 2015-12-31 0001559356 us-gaap:WarrantMember us-gaap:MinimumMember 2016-01-01 2016-03-31 0001559356 us-gaap:WarrantMember us-gaap:MaximumMember 2016-01-01 2016-03-31 0001559356 us-gaap:WarrantMember us-gaap:MinimumMember 2015-12-31 0001559356 us-gaap:WarrantMember us-gaap:MaximumMember 2015-12-31 0001559356 IMNP:SecondQuarter2016Member 2016-01-01 2016-03-31 0001559356 IMNP:ThirdQuarter2016Member 2016-01-01 2016-03-31 0001559356 IMNP:ThirdQuarter2017Member 2016-01-01 2016-03-31 0001559356 IMNP:FourthQuarter2017Member 2016-01-01 2016-03-31 0001559356 IMNP:FirstQuarter2018Member 2016-01-01 2016-03-31 0001559356 IMNP:SecondQuarter2018Member 2016-01-01 2016-03-31 0001559356 IMNP:ThirdQuarter2018Member 2016-01-01 2016-03-31 0001559356 IMNP:FourthQuarter2018Member 2016-01-01 2016-03-31 0001559356 IMNP:FirstQuarter2019Member 2016-01-01 2016-03-31 0001559356 IMNP:SecondQuarter2019Member 2016-01-01 2016-03-31 0001559356 IMNP:ThirdQuarter2019Member 2016-01-01 2016-03-31 0001559356 IMNP:FourthQuarter2019Member 2016-01-01 2016-03-31 0001559356 IMNP:SecondQuarter2020Member 2016-01-01 2016-03-31 0001559356 IMNP:SecondQuarter2016Member 2016-03-31 0001559356 IMNP:ThirdQuarter2016Member 2016-03-31 0001559356 IMNP:ThirdQuarter2017Member 2016-03-31 0001559356 IMNP:FourthQuarter2017Member 2016-03-31 0001559356 IMNP:FirstQuarter2018Member 2016-03-31 0001559356 IMNP:SecondQuarter2018Member 2016-03-31 0001559356 IMNP:ThirdQuarter2018Member 2016-03-31 0001559356 IMNP:FourthQuarter2018Member 2016-03-31 0001559356 IMNP:FirstQuarter2019Member 2016-03-31 0001559356 IMNP:SecondQuarter2019Member 2016-03-31 0001559356 IMNP:ThirdQuarter2019Member 2016-03-31 0001559356 IMNP:FourthQuarter2019Member 2016-03-31 0001559356 IMNP:SecondQuarter2020Member 2016-03-31 0001559356 us-gaap:MinimumMember 2016-01-01 2016-03-31 0001559356 us-gaap:MaximumMember 2016-01-01 2016-03-31 0001559356 IMNP:TNIBioTechIPIncMember 2012-04-23 2012-04-24 0001559356 IMNP:DrPlotnikoffMember 2012-04-23 2012-04-24 0001559356 IMNP:TNIIPManagementMember 2012-04-23 2012-04-24 0001559356 IMNP:YoungAgreementMember IMNP:DrBernardBihariMember 2012-08-12 2012-08-13 0001559356 IMNP:YoungAgreementMember 2013-01-01 2013-12-31 0001559356 IMNP:YoungAgreementMember 2013-12-31 0001559356 IMNP:SmithAgreementMember 2012-12-23 2012-12-24 0001559356 IMNP:SmithAgreementMember IMNP:InitialLicenseFeeMember 2012-12-23 2012-12-24 0001559356 IMNP:SmithAgreementMember IMNP:ExpensesMember 2012-12-23 2012-12-24 0001559356 IMNP:SmithAgreementMember 2014-09-23 2014-09-24 0001559356 IMNP:ShanAgreementMember 2013-05-01 2013-05-31 0001559356 IMNP:ShanAgreementMember 2014-08-05 2014-08-06 0001559356 2012-07-13 2012-07-14 0001559356 IMNP:GBOIGMember 2012-09-24 2012-09-25 0001559356 IMNP:AgreementswithHubeiQianjiangPharmaceuticalCompanyMember 2012-10-17 2012-10-18 0001559356 IMNP:PlaintiffClaimsMember 2014-02-01 2014-02-28 0001559356 IMNP:PlaintiffEKKrauseAndAssociatesMember 2014-02-01 2014-02-28 0001559356 IMNP:PlaintiffEKKrauseAndAssociatesMember 2015-01-01 2015-12-31 0001559356 IMNP:PlaintiffClaimsMember 2014-10-01 2014-10-31 0001559356 IMNP:PlaintiffClaimsMember 2015-05-01 2015-10-31 0001559356 us-gaap:CommonStockMember 2016-01-01 2016-03-31 0001559356 us-gaap:CommonStockMember 2016-03-31 0001559356 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-03-31 0001559356 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0001559356 IMNP:StockToBeIssuedMember 2016-01-01 2016-03-31 0001559356 IMNP:StockToBeIssuedMember 2016-03-31 0001559356 IMNP:PrepaidServiceMember 2016-01-01 2016-03-31 0001559356 IMNP:PrepaidServiceMember 2016-03-31 0001559356 us-gaap:RetainedEarningsMember 2016-01-01 2016-03-31 0001559356 us-gaap:RetainedEarningsMember 2016-03-31 0001559356 us-gaap:NoncontrollingInterestMember 2016-01-01 2016-03-31 0001559356 us-gaap:NoncontrollingInterestMember 2016-03-31 0001559356 2014-12-31 0001559356 2015-03-31 0001559356 2015-01-01 2015-12-31 0001559356 IMNP:NotesPayableNineMember 2016-03-31 0001559356 IMNP:NotesPayableTenMember 2016-03-31 0001559356 IMNP:NotesPayableNineMember 2015-12-31 0001559356 IMNP:NotesPayableTenMember 2015-12-31 0001559356 2016-02-02 2016-02-03 0001559356 us-gaap:WarrantMember 2016-03-31 0001559356 us-gaap:WarrantMember us-gaap:MinimumMember 2016-03-31 0001559356 us-gaap:WarrantMember us-gaap:MaximumMember 2016-03-31 0001559356 IMNP:SecondQuarter2021Member 2016-01-01 2016-03-31 0001559356 IMNP:SecondQuarter2021Member 2016-03-31 0001559356 2014-01-01 2014-12-31 0001559356 IMNP:OrlandoFloridaMember 2016-01-01 2016-03-31 0001559356 IMNP:OrlandoFloridaMember 2015-01-01 2015-03-31 0001559356 IMNP:MayFifteenTwoThousandSixteenMember 2016-01-01 2016-03-31 0001559356 IMNP:MrWilsonMember us-gaap:SubsequentEventMember 2016-04-28 2016-05-01 0001559356 us-gaap:SubsequentEventMember 2016-04-28 2016-05-01 0001559356 us-gaap:SubsequentEventMember 2016-05-16 0001559356 IMNP:DistributionAgreementsNigeriaMember 2013-10-01 2013-10-31 0001559356 IMNP:SupervisionAndInspectionOfManufacturingInNicaraguaMember 2013-04-22 2013-04-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure IMNP:Installments Immune Therapeutics, Inc. 0001559356 10-Q 2016-03-31 false --12-31 Smaller Reporting Company

23149

132817

191987

30852

-5958184

-6185136

17485

343434786

1140303

-660417

-347789889

-2100452

20513

351290136

1173244

-2133286

-354391171

-2144572

6331

6878

0.0001

500000000

174850047

205127530

174850047

205127530

206913301

-6645402

-2905406

-6601282

-44120

174850047

205127530

113242522

140100000

1000000

500000

19043000

1314169

270000

140000

1904

3724266

-269466

-2142535

669667

10921983

2306415

1093

2027915

277407

5191909

89639

2420377

836285

365500

312500 50000 31 24969 25000

2078199

2078199 -1364339 669667 2161559 1314169

148060

547

668

-597962

-757110

139203

-192521

486373

32600

1594

3463

2070

707000

595975

50000 95000

109038

-161135

7050

4500

0.553 0.502 0.125

497962

1000000000

148059

24731500

9372750

6331

6878

8013

P5Y

3567000

323000

393000

282136000

198312000

236671000

365006000

758342000

1077640000

1281039000

1641351000

365006

236671

2793701

2838200

100000

711500

7000

669933

200000

800000

130000

175268

100000

346000

579932

200000

750000

130000

175268

312000

245000

2015-01-27

2015-10-17

2015-07-30

2016-09-30

2016-03-09

2016-12-01

0.10

0.18

0.10

0.02

0.10

0.18

0.02

0.05

0.10

2000000

140001

346000

223500

356432

223500

6667 15600000

15600000

9131500

24731500

0.07 15.00 0.07 15.00 0.20 .50 1.50 .50 1.47 0.79 0.39

37500

525000

1500000

2941666

127500

33334

650000

1197500

4024000

135000

260000

400000

300000

12600000

5.00

1.00

15.00

1.00

1.50

0.07

.50

.14

.50

0.20

5.00

9.00

1.50

2.00

0.23

P6M

P1Y6M

P1Y9M

P2Y

P2Y3M

P2Y6M

P2Y9M

P3Y

P3Y3M

P3Y6M

P3Y9M

P4Y3M

P5Y

19043000

9272502

P12M P24M

669667

2161559

20250000

8000000

12250000

540000

300000

98000000

16006000

972000

2880384

400000

118333 1372000 2715000

165384

100000

65384

500000 the letter of intent, the Company and GBOIG intend to provide HIV/AIDS treatment to 25,000 patients and hopefully expanding to 500,000 within 24 months.

1000

0.50 2500000 0.06

75000

259894

80000

279000 210452 92590 9. Licenses and Supply Agreements   Patent and Subsidiary Acquisition   The Company entered into a share exchange agreement on April 24, 2012 to acquire all of the outstanding shares of TNI BioTech IP, Inc. (TNI IP), a biotechnology firm incorporated in Florida and formed to acquire patents related to the treatment of cancer and HIV/AIDS and autoimmune diseases, using Met-enkephalin (MENK) and Naltraxone (LDN). The goal of TNI IPs management was to enable mankind and civilization to combat fatal diseases by activating and mobilizing the bodys own immune system using TNI IPs patented use of MENK. The first patents acquired by TNI IP were acquired from Dr. Nicholas P. Plotnikoff and Professor Fengping Shan in 2012. TNI IP was acquired in exchange for 20,250,000 shares of the Companys common stock, of which 8,000,000 shares were issued to Dr. Plotnikoff for the acquisition of patents and the remaining 12,250,000 shares were issued to the founders of TNI IP in exchange for all of their right, title and interest in their TNI IP shares. The goodwill arising on the acquisition of TNI IP was valued at $98,000,000 and license agreements arising from the acquisition of TNI IP were valued at $16,006,000.   In connection with the share exchange, we entered into a Sale of Technology Agreement with Dr. Nicholas P. Plotnikoff on March 4, 2012, wherein Dr. Plotnikoff agreed to transfer and assign all of his rights, title and interest in: European Patent United Kingdom, Germany, France, Ireland EP 1401471 BI Methods for inducing sustained immune response; Russian Patent Russian Federation patent number 2313364; The Patent Office of the Peoples Republic of China, Application No.: 200810165784.8 China Patent CN1015113407 A The Patent Office of the Peoples Republic of China ISSN: 1006-2858 CN 21-1349/R; Patent Agencies Government of India Patent, Application number 1627/KOLNP/2003 number 220265 an Enkephalin Peptide Composition; and the US Patent Pending, US Patent Application 10/146.999 e. The Company received all the production formulations and technology designs from Dr. Plotnikoff necessary for the manufacturing, formulation, production and protocols of the MENK treatment of cancer and HIV/AIDS. As consideration for entering into the Sale of Technology Agreement, Dr. Plotnikoff received 8,000,000 shares of common stock, a royalty of a single-digit percentage on all sales of MENK and was granted the position of Non-Executive Chairman of the Board of Directors.   At the time of the acquisition, the valuation of goodwill and other intangible assets were determined using the fair market price for the Companys common stock, which were exchanged for shares of TNI IP. In the fourth quarter of 2012, the Company performed an annual valuation to determine whether any goodwill or intangible assets that had been acquired by the Company were impaired. The result of this valuation was that material impairments were identified. The Company recognized an impairment of the goodwill arising on the acquisition of TNI IP of $98,000,000.   Patent License Agreements   On August 13, 2012, the Company signed an exclusive License Agreement with Ms. Jacqueline Young (the Young Agreement) for the intellectual property developed by Dr. Bernard Bihari relating to treatments with opioid antagonists such as naltrexone and Met-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkins lymphoma, and non-Hodgkins lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC). The Bihari patents were acquired in exchange for 540,000 shares of the Companys common stock with a fair market value of $972,000 and assumed liabilities of $400,000, which is payable to Ms. Young over a twenty-four month period in equal installments to reimburse her for the costs of a New York City office in accordance with the Young Agreement. The patent liability at December 31, 2013 totaled $118,333. The cost of the patent totaled $1,372,000. The Company will pay the licensor a royalty payment of 1% of gross MENK sales and provide the licensor a position as non-executive chairman of the Company. In addition, we are required to make a minimum royalty in the amount of $100,000 for each year after 2014 until such time as we make a first commercial sale. The Young Agreement is valid for the life of the patents and expires on a country by country basis in each country where patent rights exist, upon the expiration of the last to expire patent in each country or in the event the patent in such country is held to be invalid and/or unenforceable (by a court or government body of competent jurisdiction) or admitted to be invalid or unenforceable. Additionally, we can cancel the Young Agreement upon 120 days written notice and shall pay all royalties and fees that have accrued under the Young Agreement. We have the exclusive rights to the intellectual property; however, Ms. Young retains a right to practice the patents licensed under the Young Agreement solely for noncommercial, academic research purposes.   On December 24, 2012, the Company signed an agreement for the acquisition of patent rights (the Smith Agreement) for the intellectual property of Dr. Jill Smith and LDN Research Group, LLC (collectively, the Licensor Parties), whose members are Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Moshe Rogosnitzky and orphan drug designation by the FDA to a novel late-stage drug, trademarked LDN, for the treatment of Pediatric Crohns disease. The patent covers methods and formulations for treatment of the inflammatory and ulcerative diseases of the bowel, using naltrexone in low doses as an opioid antagonist. These patents were acquired in exchange for 300,000 shares of our common stock with a fair market value of $2,715,000 and payment of $165,384 (consisting of a $100,000 initial license fee and payment of $65,384 of expenses), which totaled $2,880,384.   The Smith Agreement requires the Company to (i) use commercially reasonable efforts to develop, commercialize, market and sell licensed products in a manner consistent with a business plan, (ii) expend a minimum amount of funds per annum to develop and commercialize licensed products as soon as practicable, (iii) obtain all requisite regulatory approvals needed to use or sell licensed products in the field of use, and (iv) make the first commercial sale of a licensed product by March of 2017.   The Company is required to pay an annual license fee, an annual running royalty on net sales of each licensed product or a minimum royalty, whichever is greater, and a sublicense fee on payments received by the Company from sublicensees. The Company has an exclusive, worldwide license to make, have made, use, lease, import, offer for sale and sell licensed products and to use the method under the patent rights. The Smith Agreement will terminate on the expiration or abandonment of the last patent to expire or ten years after the sale of the first licensed product. The Company may terminate the Smith Agreement upon 90 days written notice, provided all sublicenses are terminated and all amounts due and owing are paid to the Licensor Parties. The Licensor Parties may terminate the agreement ten days after notice to the Company if the Company is ten days late in payment or there is a breach that remains uncured for ten days after written notice of such breach.   The Company is also required to pay milestone payments after substantial achievement of certain milestone events for each licensed product including payment: upon initiation of each Phase III trial; upon positive completion of each Phase III clinical trial of the therapeutic use of an LDN compound in the field of use; when a New Drug Application (NDA) is accepted for review by the FDA; and when FDA approval to market the NDA is approved. The Company will issue shares upon reaching certain milestones including upon the first dosing of the first patient in a Phase III clinical trial for each licensed product, upon the first sale of each licensed product, and upon the achievement of a set dollar amount in cumulative sales for each licensed product covered by NDAs.   As part of the Smith Agreement, the Company has the right to apply to the FDA for the transfer of the orphan drug status for the use of naltrexone for the treatment of pediatric Crohns disease and ulcerative colitis, the Investigation New Drug Application (IND), and the right to acquire the relevant clinical data set from Dr. Jill Smith. Dr. Jill Smith made arrangements to transfer the IND to the Company as well as the relevant clinical data set, and the FDA has acknowledged that the Company is now the sponsor for this IND.   On September 24, 2014, the Company and the Licensor Parties jointly agreed to terminate the Smith Agreement, and in place thereof, have the Licensor Parties grant a similar license in their patent rights to Cytocom Inc. pursuant to a Patent License Agreement between the Licensor Parties, Cytocom Inc. and the Company with substantially similar terms as set forth in the Smith Agreement. Pursuant to this agreement, the Company issued 1,000,000 shares of its common stock valued at $270,000, upon execution to the Licensor Parties and the Company guaranteed the obligations of Cytocom Inc. to the Licensor Parties under the agreement.   On January 18, 2013, the Company signed an exclusive licensing agreement with The Penn State Research Foundation to license all of the intellectual property developed by Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Dr. Jill P. Smith for the treatment of cancer titled Opioid Growth Factor and Cancer and Combination Therapy with Opioid Growth Factor and Taxanes for the Treatment of Cancer (the Foundation Agreement).   The Foundation Agreement requires the Company to: (a) use commercially reasonable efforts to develop, commercialize, market and sell licensed products in a manner consistent with a business plan; (b) expend a minimum amount of funds per annum to develop and commercialize licensed products as soon as practicable; (c) obtain all requisite regulatory approvals needed to use or sell licensed products in the field of use; and (d) make the first commercial sale of a licensed product by December 31, 2016.   The Foundation Agreement provides that the Company must pay to the licensor an initial license fee, a license maintenance fee on each anniversary of the effective date of the Foundation Agreement, and an annual running royalty on net sales for each licensed product or a minimum royalty, whichever is greater. In addition, the Company must pay a sublicense fee on payments received by the Company from sublicensees.   The Foundation Agreement also requires the Company to make payments upon the achievement of certain milestone events including: initiation of each Phase II trial; initiation of each Phase III trial; when the NDA is accepted for review by the FDA; and when FDA approval to market is approved. The Company must also issue shares upon certain milestones including upon the first dosing of the first patient in a Phase II clinical trial for each licensed product, upon the first dosing of the first patient in a Phase III clinical trial for each licensed product, upon the first sale of each licensed product, and upon the achievement of a set dollar amount of cumulative sales for each licensed product covered by NDAs.   The Foundation Agreement terminates on the expiration or abandonment of the last patent to expire or become abandoned. The Company may terminate the Foundation Agreement at any time upon 60 days prior written notice and ceasing to make and sell all licensed products, the termination of all sublicenses and payment of all monies owed under the Foundation Agreement. The licensor may terminate the agreement 30 days after notice to the Company if the Company is 30 days late in payment or a breach that remains uncured for 45 days after written notice of such breach.   In May of 2013, the Company executed a Patent License Agreement with Professor Fengping Shan (the Shan Agreement) pursuant to which it obtained exclusive rights to develop and commercialize the licensed technology. The licensed technology is the intellectual property developed and owned by Professor Shan (i) relating to the treatment of a variety of diseases and conditions with MENK including multiple forms of lymphoma and cancer and (ii) a treatment method for humans infected with the HLTV-III (AIDS) virus including AIDS and AIDS related complex (ARC). The licensed technology includes the methods and formulations for these treatments including all INDs, communications with regulatory agencies, patient data, and letters relating to these treatments. The licensed technology also includes certain patents developed by Professor Shan. Under the Shan Agreement, the Company must issue 500,000 shares to Professor Shan upon final transfer of the licenses, and reimburse Professor Shan for all out of pocket expenses in connection with the patents. The Company will pay Professor Shan a running royalty on gross sales subject to decreases if third party intellectual property is needed to complete such sale or product. The Shan Agreement lasts for the duration of each of the licensed patents however the Company may terminate the Shan Agreement on 120 days written notice to Professor Shan.   On August 6, 2014, Professor Fengping Shan executed an Assignment pursuant to which he transferred to the Company his entire right, title and interest in and to the licensed patents under the Shan Agreement and CN 201210302259 Application of combination of low-dose naltrexone and methionine-enkephalin to preparation of anti-cancer drug for the consideration of 500,000 shares of common stock valued at $140,000.

1. Organization and Description of Business   Immune Therapeutics, Inc. (the Company) was initially incorporated in Florida on December 2, 1993 as Resort Clubs International, Inc. (Resort Clubs). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (Galliano) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (pH Environmental).   On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2014 changing our name to Immune Therapeutics, Inc.   The Company currently operates out of Orlando, Florida. In July 2012, the Companys focus turned to acquiring patents that would protect and advance the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (LDN) and Methionine [Met5]-enkephalin (MENK). The Companys therapies are believed to stimulate and/or regulate the immune system in such a way that they provide the potential to treat a variety of diseases. We believe our therapies may be able to correct abnormalities or deficiencies in the immune system in diseases such as HIV infection, autoimmune disease, immune disorders, or cancer; all of which can lead to disease progression and life-threatening situations when the immune system is not functioning optimally.   In October 2012, the Company formed TNI BioTech International, Ltd., a BVI company in Tortola, British Virgin Islands, which was set up to allow the Company to market and sell LDN in those countries outside the U.S. in which we have been able to obtain approval to sell the Companys products.   In August 2013, the Company formed its United Kingdom subsidiary, TNI BioTech, LTD (the UK Subsidiary). The UK Subsidiary received approval to be considered a micro, small or medium-sized enterprise (SME) with the European Medicines Agency (EMA) on August 21, 2013. The designation provides the UK Subsidiary with significant discounts when holding meetings or submitting filings to the EMA. On September 19, 2013, the UK Subsidiary submitted a pre-submission package to the EMA regarding Crohns Disease. The EMA granted the UK Subsidiary a meeting that took place on September 27, 2013. The UK Subsidiary is eligible to benefit from the provisions for administrative and financial assistance for SMEs set out in Regulation (EC) No 2049/2005. The Company will apply to obtain EMA benefits once funding becomes available.   In December 2013, the Company formed a new subsidiary, Cytocom Inc., to focus on conducting LDN and MENK clinical trials in the United States. In December 2014, the Company finalized the distribution of common stock of Cytocom Inc. to its shareholders. As part of the transaction, the Company retained exclusive rights to all international patents, in-country approvals, formulations, trademarks, manufacturing, marketing, sales, and distributions rights in emerging nations, including Africa, Central America, South America, Russia, India, China, Far East, and The Commonwealth of Independent States (former Soviet Union). The Company will continue to have access to existing clinical data as well as any new data generated by Cytocom Inc. during drug development. On December 8, 2014, the number of Cytocom Inc. shares of common stock that were issued to our shareholders totaled 113,242,522 shares. In connection with the transaction, Cytocom Inc. issued 140,100,000 shares of its common stock to the Company, which gave the Company a 55.3% equity interest in Cytocom Inc. on that date. The Companys equity interest has since been reduced to 50.2% at March 31, 2016, by subsequent issuances of Cytocom common stock to shareholders.   In March 2014, the Company incorporated Airmed Biopharma Limited, an Irish corporation with an address in Dublin, Ireland, and Airmed Holdings Limited, an Irish company domiciled in Bermuda. The Irish companies were set up to benefit from incentives granted by the Irish government for the establishment of pharmaceutical companies (many of the worlds leading pharmaceutical companies have located in Ireland), and so that the Company could take advantage of Irelands status as a member of the European Union and the European Economic Area. An Irish limited liability company enjoys a low corporate income tax rate of 12.5%, one of the lowest in the world. The Irish-domiciled company hopes to qualify for tax incentives for Irish holding/headquartered companies and to benefit from the network of double tax treaties that reduce withholding taxes. TNI BioTech International, Ltd. will manage our international distribution, using product that is manufactured in Ireland and elsewhere.   We are focused on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases and immune disorders by combating these severe and fatal diseases through the stimulation and/or regulation of the bodys immune system. Our growth strategy includes the near-term commercialization of our existing immunotherapies targeting cancer, Crohns disease and/or HIV/AIDS.   Going Concern   The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidate and the achievement of a level of revenues adequate to support the Companys cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. Based on the Companys operating plan, existing working capital at December 31, 2015 was not sufficient to meet the cash requirements to fund planned operations through December 31, 2016 without additional sources of cash. These conditions raise substantial doubt about the Companys ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Companys assets and the satisfaction of liabilities in the normal course of business.   The Company experienced a net loss from operations of $6,645,402, and used cash and cash equivalents for operations in the amount of $497,962 during the quarter ended March 31, 2016, resulting in stockholders deficit of $6,185,136 at that date.

2. Summary of Significant Accounting Policies   Basis of Presentation   The accompanying consolidated financial statements have been prepared in accordance with United States (U.S.) generally accepted accounting principles (U.S. GAAP) and include all adjustments (consisting of only normal recurring adjustments, unless otherwise indicated) necessary for the fair presentation of the Companys financial position for the periods presented.   The Company qualifies as an emerging growth company as defined in Section 101 of the Jumpstart our Business Startups Act (JOBS Act) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2015. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.   Use of Estimates   The preparation of the Companys financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.   Cash, Cash Equivalents, and Short-Term Investments   The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.   Concentration of Credit Risk   Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At March 31, 2016, the Company has no uninsured cash balances.   Fair Value of Financial Instruments   In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.   Fair Value Measurements   The ASC Topic 820, Fair Value Measurements, defines fair value, establishes a framework for measuring fair value in accordance with U.S. generally accepted accounting principles, and requires certain disclosures about fair value measurements. In general, fair values of financial instruments are based upon quoted market prices, where available. If such quoted market prices are not available, fair value is based upon internally developed models that primarily use, as inputs, observable market-based parameters. Valuation adjustments may be made to ensure that financial instruments are recorded at fair value. These adjustments may include amounts to reflect counterparty credit quality and the customers creditworthiness, among other things, as well as unobservable parameters. Any such valuation adjustments are applied consistently over time.   Property and Equipment   Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the quarters ended March 31, 2016 and March 31, 2015 was $547 and $668, respectively.   Intangible Assets   Costs incurred to acquire and/or develop the Companys product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of seven to sixteen years. Intangible assets are stated at the lower of cost or estimated fair market value. During the quarters ended March 31, 2016 and March 31, 2015, the Company did not capitalize any such costs. (See Note 10). Amortization expense for the quarters ended March 31, 2016 and March 31, 2015 was $0 and $148,059, respectively.   Impairment of Long-Lived Assets   The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, Property, Plant and Equipment. If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value. No impairment losses were recognized for the quarters ended March 31, 2016 and March 31, 2015.   Research and Development Costs   Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Companys behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.   Income Taxes   The Company follows FASB ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.   The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of December 31, 2015, and 2014, the Company does not have a liability for unrecognized tax uncertainties.   The Companys policy is to record interest and penalties on uncertain tax positions as income tax expense. At the end of the quarters ended March 31, 2016 and March 31, 2015, the Company had not accrued any interest or penalties related to uncertain tax positions.   Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration   The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Companys common stock at the date of the agreement.   The Companys accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, Equity-Based Payments to Non-Employees. The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendors performance is complete.   Non-controlling Interest   In accordance with ASC 810, Consolidation, the Company consolidates Cytocom, Inc. The non-controlling interests in Cytocom represent the interests of outside shareholders in the equity and results of operations of Cytocom.   Net Loss per Share   Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Companys net loss position.   A calculation of basic and diluted net loss per share follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">For the three months ended March 31,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Historical net loss per share:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Numerator</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%; line-height: 115%">Net loss</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(6,645,402</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(2,905,406</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Non-controlling interest</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(44,120</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(124,065</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Net loss attributed to Common stockholders</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(6,601,282</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(2,781,341</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Denominator</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Weighted-average common shares outstandingDenominator for basic and diluted net loss per share</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">190,923,381</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">138,795,044</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Basic and diluted net loss per share attributed to common stockholders</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(0.03</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(0.02</td> <td style="line-height: 115%">)</td></tr> </table>   The Companys potential dilutive securities which include stock and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common stock outstanding used to calculate both basic and diluted net loss per share is the same.   The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">For the three months ended March 31,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Warrants to purchase Common stock</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">24,731,500</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">9,372,750</td> <td style="line-height: 115%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   Recent Accounting Standards   During the quarter ended March 31, 2016, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Companys consolidated financial statements.

3. Property and Equipment   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Property and equipment:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 68%; line-height: 115%">Computer equipment</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">8,013</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">8,013</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Less accumulated depreciation</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(6,878</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(6,331</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Property and equipment, net</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1,135</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1,682</td> <td style="line-height: 115%"> </td></tr> </table>   The Company utilizes the straight-line method for depreciation, using three to five-year depreciable asset lives. Depreciation expense was not material for all periods presented.

4. Accrued Liabilities   Accrued expenses and other liabilities consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">(in thousands)</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; line-height: 115%">Accrued payroll to officers and others</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">1,077,640</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">758,342</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Accrued interest - notes payable</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">365,006</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">236,671</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Estimated legal settlement</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">198,312</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">282,136</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Other accrued liabilities</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">393</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">323</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">State payroll taxes</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">3,567</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total accrued expenses and other liabilities</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1,641,351</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1,281,039</td> <td style="line-height: 115%"> </td></tr> </table>

5. Notes Payable   Notes payable consist of the following: <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; text-align: justify; line-height: 115%">Promissory note issued July 29, 2014 to Ira Gaines. The note matures on January 27, 2015 and earns interest at a rate of 18% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender.</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">100,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">100,000</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued between November 26, 2014 and September 30, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Companys gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $346,000 were in default at March 31, 2016, as the Company was unable to pay installments on those notes on their due dates. No demands for repayment have been made by the lenders. In the quarter ended March 31, 2016, $365,500 of these notes and their accompanying interest were converted into 5,191,909 shares of Immune Therapeutics common stock.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">346,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">711,500</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued October 17, 2014 to Roger Bozarth. The note matures on October 17, 2015 and earns interest at a rate of 2% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. In the quarter ended March 31, 2016, this note and the accompanying interest was converted into 89,639 shares of Immune Therapeutics common stock.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">7,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued between May 1, 2015 and September 30, 2015, and maturing between June 14, 2015 and December 31, 2015. Lenders on loans aggregating $356,432 earn interest at rates between 10% and 18% per annum. On loans aggregating $223,500, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $223,500 were in default at March 31, 2016, as the Company was unable to repay those notes on their due dates. No demands for repayment have been made by the lenders. In the quarter ended March 31, 2016, $140,001 of these notes and their accompanying interest were converted into 2,420,377 shares of Immune Therapeutics common stock.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">579,932</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">669,933</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued January 26, 2015 to Robert J. Dailey. The note is senior to, and has priority in right of payment over, all indebtedness of the Company. The note earns interest at a rate of 2% per annum and was due on July 30, 2015. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">200,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">200,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on September 30, 2016.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">750,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">800,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued in December 2015. Lenders earn interest at a rate of 10% per month. Notes are repayable on March 9, 2016. The Company was unable to repay the note at maturity and the note is in default. The Company is obligated to pay late-payment penalties totaling $6,667 per day.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">130,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">130,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued November 24, 2015 as settlement of amounts owing to a law firm. The Lender earns interest at the rate of 10% per annum. The note is repayable in full on December 1, 2016.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">175,268</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">175,268</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued between January 1, 2016 and March 31, 2016. Lenders earn interest at a rate of 10% per month. Notes are repayable in one year.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">312,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued February 3, 2016, payable in 90 days which includes an original issue discount of $40,000 and expenses of $5,000, resulting in net proceeds of $200,000.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">245,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">2,838,200</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">2,793,701</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Less: Current Portion</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(2,838,200</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(2,793,701</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Long-Term debt, less current portion</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> </table>   As of March 31, 2016, the Company had accrued $365,006 in unpaid interest, compared to $236,671 as of December 31, 2015

6. Capital StructureCommon Stock and Common Stock Purchase Warrants   Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.   As of March 31, 2016 and 2015, the Company was authorized to issue 500,000,000 common shares at a par value of $0.0001 per share.   As of March 31, 2016, the Company had 205,127,530 shares of common stock outstanding and 178,850,047 outstanding as of December 31, 2015.   Stock Warrants   In the quarter ended March 31, 2016, the Company issued 15,600,000 warrants.   There were no modifications of the terms of any warrants issued by the Company in the quarters ended March 31, 2016 and 2015.   Following is a summary of outstanding stock warrants at March 31, 2016 and activity during the three months then ended:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Number of Shares</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Exercise Price</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Price</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 115%">Warrants as of December 31, 2015</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 14%; text-align: right; line-height: 115%">9,131,500</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">0.07-15.00</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">1.47</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Issued in 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">15,600,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">.020-2.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.39</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expired</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Warrants as of March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">24,731,500</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"> 0.07-15.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">0.79</td> <td style="line-height: 115%"> </td></tr> </table>   Summary of outstanding warrants as of March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">Expiration Date</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Number of Shares</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Exercise Price</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Remaining Life (years)</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 115%">Second Quarter 2016</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 14%; text-align: right; line-height: 115%">37,500</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">5.00</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 14%; text-align: right; line-height: 115%">.25</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Third Quarter 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">525,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.00-5.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">.50</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Third Quarter 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,500,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.50</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Fourth Quarter 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2,941,666</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.00-9.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.75</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">First Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">127,500</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">15.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.00</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Second Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">33,334</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">15.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.25</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Third Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">650,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.00-1.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.50</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Fourth Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,197,500</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.00-1.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.75</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">First Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,024,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.50-2.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.00</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Second Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">135,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.070.23</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.25</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Third Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">260,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.50</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Fourth Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">400,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.14</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.75</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Second Quarter 2020</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">300,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4.25</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">First Quarter 2021</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">12,600,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.20</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5.00</td> <td style="line-height: 115%"> </td></tr> </table>

7. Stock Compensation   Shares Issued for Services   During the quarters ended March 31, 2016 and 2015, the Company issued 19,043,000 and 9,272,502 shares of common stock respectively for consulting fees. The Company valued these shares at $1,314,169 and $1,712,876 respectively, based upon the fair market value of the common stock at the dates of the agreements. The consulting fees are amortized over the contract periods which are typically between 12 and 24 months. The amortization of prepaid services totaled $669,667 and $2,161,559 for the quarters ended March 31, 2016 and 2015.

8. Income Taxes - Results of Operations   There was no income tax expense reflected in the results of operations for the quarters ended March 31, 2016 and 2015 because the Company incurred a net loss in both quarters.   The Company has recognized no tax benefit for the losses generated for the periods through December 31, 2015. ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Companys ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided.   Our effective tax rate for fiscal years 2015 and 2014 was 0%. Our tax rate can be affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. It may also be affected by discrete items that may occur in any given year, but are not consistent from year to year.   As of December 31, 2015, we have estimated federal and state income tax net operating loss (NOL) carry-forwards of approximately $66,500,000, which will expire in 2032-2035.

10. Commitments and Contingencies   Malawi Treatment Facilities   On July 14, 2012, GB Oncology and Imaging Group LTD (GBOIG) in partnership with the Company signed a letter of intent agreement to collaborate with the Government of Malawi to assist in expanding the treatment of cancer, HIV/AIDS and other infectious diseases.   In December of 2014, the Government of Malawi completed an oncology clinic at the Queen Elizabeth Central Hospital in Blantyre, Malawi for the treatment of cancer and infectious diseases. In 2015, the Company submitted protocols seeking permission from the Pharmacy, Medicines and Poisons Board of Malawi (PMPB) to conduct two trials involving Lodonal in Malawi:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 115%">a. </td> <td style="text-align: justify; line-height: 115%">The first protocol, submitted jointly with The Jack Brewer Foundation (JBF Worldwide), received PMPB approval on November 11, 2015. The protocol covers a 12-month trial for a Single Visit Approach to Cervical Cancer Prevention. The approach is designed to deliver a preventive and simple procedure that can be performed in a clinical setting without the use of a laboratory and to allow for immediate treatment of any precancerous lesions utilizing Wallach LL100 Cryosurgical systems. The protocol provides for 50% of the patient group to be put on Lodonal to determine if the drug lowers the number of opportunistic infections during the year, and if it can be shown that LDN increases CD4, CE8, NK and T cell count, which would show that the incidence rates of opportunistic infection could decrease with Lodonal and that Lodonal could be used as a prophylaxis to prevent substantial HIV-related morbidity in Malawi. The final trial agreement with PMPB was signed in February 2016. Lodonal pills have been produced in Nicaragua in anticipation of the trial. Shipments will commence once the trial is approved.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%">b. </td> <td style="text-align: justify; line-height: 115%">The second protocol, which has not yet been approved, covers a trial using Lodonal for the treatment of cancer. </td></tr> </table>   The Company and GBOIG will work with the government of Malawi to open and operate other clinics that provide treatments for HIV/AIDS, cancer and other infectious diseases. Under the letter of intent, the Company and GBOIG intend to provide HIV/AIDS treatment to 25,000 patients and hopefully expanding to 500,000 within 24 months. The Company shall contribute $1,000 in initial capital to the venture. The Company shall be allocated 50% of the net income from the venture. Either party may terminate the venture with 180 days notice to the other party prior to the one-year anniversary of the Agreement. After the one-year anniversary, the agreement may only be terminated with 180 days notice to the other party if the other party has breached the Agreement.   GBOIG, a subsidiary of GB Energie LLC, is a Washington D.C. based minority woman-owned business managed by Dr. Gloria B. Herndon. Dr. Herndon is a former director of the Company. Dr. Herndons directorship with the Company ended September 4, 2014.   Open an Oncology and Infectious Disease Center in Malawi at Queen Elizabeth Central Hospital   On September 25, 2012, GBOIG, in partnership with the Company, signed an agreement with the Government of Malawi to open an outpatient clinic at Queen Elizabeth Central Hospital (in Malawi) for the treatment of cancer and infectious disease. The duration of the Agreement shall be for 25 years with an optional 10-year renewal to be indicated by the Government of Malawi at least three years prior to the expiration of the term. The Government of Malawi will bear the upfront costs for the agreement of $2,500,000.   Distribution Agreements in Nigeria   In October 2013, the Company announced the signing of a Distribution Agreement with AHAR Pharma, a Nigerian company, to market Lodonal in Nigeria for the treatment of autoimmune diseases and cancer. AHAR intends to distribute Lodonal through a local distributor network, an Internet client base and directly to hospitals, pharmacists and doctors in Nigeria. Under the agreement, the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal product to cover AHAR Pharmas first-year purchase commitment.   In August 2015, the Company announced the signing of a letter of intent with GB Pharma/AHAR and Fidson Healthcare Plc., in terms of which Fidson will promote LodonalTM upon execution of a definitive agreement between the companies.   In April 2016, the Company announced that Nigerias National Agency for Food and Drug Administration and Control (NAFDAC) had approved its LodonalTM as an over the counter, non-toxic adjunct therapy in the treatment of HIV/AIDS and immune system regulator. NAFDAC is the Nigerian agency under the Federal Ministry of Health that is responsible for regulating and controlling the manufacture, import/export, distribution, sale and use of food and drugs. Its approval clears the way for the Company and its distribution partners to complete the registration of LodonalTM for sale in Nigeria.   Agreements with Hubei Qianjiang Pharmaceutical Company   On October 18, 2012, the Company and Hubei Qianjiang Pharmaceutical Co., Ltd. (Qianjiang Pharmaceutical), signed a Venture Cooperation Agreement on New Drug Methionine Enkephalin (the Venture Agreement) pursuant to which Qianjiang Pharmaceutical acquired an exclusive license for the production of MENK in China. The Venture Agreement requires that Qianjiang Pharmaceutical conduct drug research and pilot testing for MENK, organize pre-clinical studies, and apply for clinical trials for MENK with the Chinese State Food and Drug Administration. Under the Venture Agreement, Qianjiang Pharmaceutical must open a co-administration account for the development of MENK in China. Qianjiang Pharmaceutical must pay the Company, upon the marketing of MENK products, a half-year amount equaling 6% of its gross sales from MENK of the preceding half year. The Company may cancel the Venture Agreement if Qianjiang Pharmaceutical does not pay expenses for a period exceeding six months or does not commence clinical trials within 12-months after receiving certain approvals. Qianjiang Pharmaceutical may cancel the Venture Agreement if the Company fails to perform its obligations for a period of six months or the failure to receive approval of clinical trials is due to the Companys MENK technologies. The Venture Agreement was amended on February 24, 2013 to expand the clinical trials from pancreatic to both pancreatic and liver cancer and amended on March 6, 2014 to require Qianjiang Pharmaceutical to commence studies and clinical trials in China and place funds in the co-administration account.   On August 6, 2014, the Company entered into a Supplementary Agreement on New Drug Methionine Enkephalin Cooperation (the Amendment) with Qianjiang Pharmaceutical, amending the Venture Agreement, as amended. The Company and Qianjiang Pharmaceutical executed the Amendment to accelerate clinical trials in both the United States and China, and agreed to immediately initiate three month Good Laboratory Practice (GLP) Toxicology Studies (rat and dog) within 30 days of signing the Amendment. The Amendment requires that the GLP Toxicology Studies Trials are conducted in China in accordance with international standards and standards acceptable to the FDA and that the studies include the following:   Exploratory Toxicology (nGLP) -Dose range finding studies - Different species and methods of administration - Multiple dosing regimens - Estimate the response vs. dose given   Definitive Toxicology (GLP) - Performed in collaboration with Calvert Laboratories (USA) and MPI/Medicillon (China) - General toxicology studies - Different species and methods of administration - Immunogenicity study with NHPs   Special Toxicology Studies (planned)   Pursuant to the Amendment, Qianjiang Pharmaceutical will make certain funds available from the co-administrative account opened by Qianjiang Pharmaceutical under the Venture Agreement, in accordance with an approved budget and timeline set forth in the Amendment. A portion of these funds are expected to be used by Cytocom to run PK and Dosing trials for MENK in the United States. The Amendment requires Cytocom and Qianjiang Pharmaceutical to meet with the China State Food and Drug Administration to determine that PK and Dosing Trials completed in the United States will be acceptable. All developments and trials run by Cytocom in the U.S. or the European Union will be used for requesting registration approval in China.   In February 2013, the Company signed a Strategic Framework Agreement for Cooperation with Qianjiang Pharmaceutical. Under the agreement, the parties will work together to further the development of new products and conduct research and development on the Companys licensed patented technology. Specifically, the parties aim to co-invest to develop and market products focusing on HIV, cancer and related autoimmune system therapies, develop co-ventured manufacturing facilities in China, and develop co-ventured distribution of the developed products in China and Africa. The agreement does not have a definitive term, as each new agreement resulting from the cooperation will set forth the material terms, including, but not limited to, fees, duration and termination therein.   Supervision and Inspection of Manufacturing in Nicaragua   On April 23, 2013, the Company signed a Contract with ViPharma for the Supervision and Inspection of Manufacturing Processes as part of its negotiations for a contract for the manufacturing of LDN in a tablet, capsule and/or cream. The contract sets out the terms and conditions under which ViPharma will carry out the services of inspecting and supervising the manufacturing and packaging processes of LDN and ensure compliance with the FDAs Current Good Manufacturing Practice regulations (cGMP) and the Companys specifications. ViPharma will carry out its obligations in whatever Latin American country the Company ultimately decides to manufacture LDN. Under the contract, ViPharma has the exclusive rights to supervise and inspect all manufacturing processes of LDN in Latin America. The initial term of the agreement is ten years commencing in September 2013, with automatic five-year renewal terms provided neither party is in breach. The agreement may be terminated by (i) mutual agreement, (ii) in the event of a breach after a 45 day cure period or (iii) by either party upon provision of written notice at least 90 days before the end of the agreement, provided however that if the Company terminates the contract without cause it will be required to pay ViPharma a $10 million penalty.   Operating Leases   At March 31, 2016, the Company was a party to an agreement to lease office space in Orlando, Florida. Rent expense for the quarters ended March 31, 2016 and 2015 was $(114,794) and $18,319, respectively. The 2016 expense reflects the reversal of accruals for rent expense in prior years, including the settlement with E.J. Krause & Associates, Inc. referred to in Legal Proceedings below.   Legal Proceedings   In October 2014, a claim was filed for breach of contract and unjust enrichment in the United States District Court, Middle District of Florida, Orlando Division, QS Pharma, LLC v. TNI BioTech, Inc. n/k/a Immune Therapeutics, Inc., in which the named plaintiff claims that we breached various proposals between the parties. The plaintiff was seeking an amount of damages to be proven at trial and pre-judgment interest. The plaintiff filed a Motion for Order of Default, which the court entered against the Company in favor of the plaintiff on December 15, 2014. In May and October 2015, under a garnishment order the plaintiff withdrew $92,590 from the Companys bank accounts towards settlement of the claim. In 2016, the Company agreed upon a full settlement of the balance owed for $80,000, which it paid in April 2016.   In February 2015, a claim was filed for breach of contract and unjust enrichment in the Circuit Court for Montgomery County, Maryland, E.J. Krause & Associates, Inc. v. TNI BioTech, Inc., in which the named plaintiff claims that the Company breached a sub-sublease. In April 2016 the parties settled the claim, agreeing that the Company would pay a total of $198,312 in 12 monthly installments commencing May 15, 2016.

11. Subsequent Events   On May 1, 2016, the Company entered into a one-year employment agreement with Robert Wilson, the son of the Companys Chief Executive Officer, as the Companys Senior Content and Web Developer. The terms of the agreement provide for payment to Mr. Wilson of an annual base salary of $120,000, and health insurance coverage.   On May 9, 2016, the Company and KRS Global Bio Technology, Inc. mutually agreed to terminate their Contract for the Compounding of Pharmaceutical Products dated December 8, 2014.   Between March 31, 2016 and May 16, 2016 the Company issued promissory notes aggregating $961,250 and paid off notes totaling $245,000.   The Company issued 1,786,285 shares of common stock between March 31, 2016 and May 16, 2016, of which, 450,000 shares are for consulting fees, 836,285 shares are for debt conversions and 500,000 shares are for loan origination fees.   As of May 16, 2016, the Company had outstanding 206,913,301 shares of common stock.

A calculation of basic and diluted net loss per share follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">For the three months ended March 31,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Historical net loss per share:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Numerator</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%; line-height: 115%">Net loss</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(6,645,402</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(2,905,406</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Non-controlling interest</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(44,120</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(124,065</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Net loss attributed to Common stockholders</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(6,601,282</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(2,781,341</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Denominator</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Weighted-average common shares outstandingDenominator for basic and diluted net loss per share</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">190,923,381</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">138,795,044</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Basic and diluted net loss per share attributed to common stockholders</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(0.03</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(0.02</td> <td style="line-height: 115%">)</td></tr> </table>

The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">For the three months ended March 31,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%; line-height: 115%">Warrants to purchase Common stock</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">24,731,500</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">9,372,750</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Property and equipment:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 68%; line-height: 115%">Computer equipment</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">8,013</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">8,013</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Less accumulated depreciation</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(6,878</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(6,331</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Property and equipment, net</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1,135</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1,682</td> <td style="line-height: 115%"> </td></tr> </table>

Accrued expenses and other liabilities consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="text-align: center; line-height: 115%">(in thousands)</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; line-height: 115%">Accrued payroll to officers and others</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">1,077,640</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">758,342</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Accrued interest - notes payable</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">365,006</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">236,671</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Estimated legal settlement</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">198,312</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">282,136</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Other accrued liabilities</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">393</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">323</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">State payroll taxes</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">3,567</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total accrued expenses and other liabilities</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1,641,351</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1,281,039</td> <td style="line-height: 115%"> </td></tr> </table>

Notes payable consist of the following: <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; text-align: justify; line-height: 115%">Promissory note issued July 29, 2014 to Ira Gaines. The note matures on January 27, 2015 and earns interest at a rate of 18% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender.</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 13%; text-align: right; line-height: 115%">100,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 15%; text-align: right; line-height: 115%">100,000</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued between November 26, 2014 and September 30, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Companys gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $346,000 were in default at March 31, 2016, as the Company was unable to pay installments on those notes on their due dates. No demands for repayment have been made by the lenders. In the quarter ended March 31, 2016, $365,500 of these notes and their accompanying interest were converted into 5,191,909 shares of Immune Therapeutics common stock.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">346,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">711,500</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued October 17, 2014 to Roger Bozarth. The note matures on October 17, 2015 and earns interest at a rate of 2% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. In the quarter ended March 31, 2016, this note and the accompanying interest was converted into 89,639 shares of Immune Therapeutics common stock.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">7,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued between May 1, 2015 and September 30, 2015, and maturing between June 14, 2015 and December 31, 2015. Lenders on loans aggregating $356,432 earn interest at rates between 10% and 18% per annum. On loans aggregating $223,500, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $223,500 were in default at March 31, 2016, as the Company was unable to repay those notes on their due dates. No demands for repayment have been made by the lenders. In the quarter ended March 31, 2016, $140,001 of these notes and their accompanying interest were converted into 2,420,377 shares of Immune Therapeutics common stock.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">579,932</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">669,933</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued January 26, 2015 to Robert J. Dailey. The note is senior to, and has priority in right of payment over, all indebtedness of the Company. The note earns interest at a rate of 2% per annum and was due on July 30, 2015. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">200,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">200,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on September 30, 2016.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">750,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">800,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued in December 2015. Lenders earn interest at a rate of 10% per month. Notes are repayable on March 9, 2016. The Company was unable to repay the note at maturity and the note is in default. The Company is obligated to pay late-payment penalties totaling $6,667 per day.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">130,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">130,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued November 24, 2015 as settlement of amounts owing to a law firm. The Lender earns interest at the rate of 10% per annum. The note is repayable in full on December 1, 2016.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">175,268</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">175,268</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory notes issued between January 1, 2016 and March 31, 2016. Lenders earn interest at a rate of 10% per month. Notes are repayable in one year.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">312,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Promissory note issued February 3, 2016, payable in 90 days which includes an original issue discount of $40,000 and expenses of $5,000, resulting in net proceeds of $200,000.</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">245,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">2,838,200</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">2,793,701</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Less: Current Portion</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(2,838,200</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(2,793,701</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Long-Term debt, less current portion</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> </table>

Following is a summary of outstanding stock warrants at March 31, 2016 and activity during the three months then ended:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Number of Shares</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Exercise Price</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Price</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 115%">Warrants as of December 31, 2015</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 14%; text-align: right; line-height: 115%">9,131,500</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">0.07-15.00</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">1.47</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Issued in 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">15,600,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">.020-2.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.39</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expired</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Warrants as of March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">24,731,500</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"> 0.07-15.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">0.79</td> <td style="line-height: 115%"> </td></tr> </table>

Summary of outstanding warrants as of March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 115%">Expiration Date</td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Number of Shares</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Exercise Price</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Remaining Life (years)</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 115%">Second Quarter 2016</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 14%; text-align: right; line-height: 115%">37,500</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">5.00</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 14%; text-align: right; line-height: 115%">.25</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Third Quarter 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">525,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.00-5.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">.50</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Third Quarter 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,500,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.50</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Fourth Quarter 2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2,941,666</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.00-9.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1.75</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">First Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">127,500</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">15.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.00</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Second Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">33,334</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">15.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.25</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Third Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">650,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.00-1.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.50</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Fourth Quarter 2018</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,197,500</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.00-1.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.75</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">First Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,024,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.50-2.00</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.00</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Second Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">135,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.070.23</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.25</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Third Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">260,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.50</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Fourth Quarter 2019</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">400,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.14</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.75</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Second Quarter 2020</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">300,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.50</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4.25</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">First Quarter 2021</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">12,600,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.20</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">5.00</td> <td style="line-height: 115%"> </td></tr> </table>

53205

147236

-114794

18319

2306415

Q1 2016

39346

153441

1594

16197

19660

41228

154776

200

1682

1135

5999412

6339912

2793701

2838200

1281039

1641351

1924672

1860361

5999412

6339912

41228

154776

-2100452

-2144572

-3857732

-4040564

-347789889

-354391171

-660417 -2133286 1140303 1173244

343434786

351290136

17485

20513

3463

2070

4983082

2889431

547

148727

2078199 1983837 2161559

-18842

177157

939341

401988

-4979619

-2887361

-1665783

-18045

-1364339

301444

18045

190923381

138795044

-0.03

-0.02

-6601282

-2781341

-44120

-124065

657000

500975

Basis of Presentation   The accompanying consolidated financial statements have been prepared in accordance with United States (U.S.) generally accepted accounting principles (U.S. GAAP) and include all adjustments (consisting of only normal recurring adjustments, unless otherwise indicated) necessary for the fair presentation of the Companys financial position for the periods presented.   The Company qualifies as an emerging growth company as defined in Section 101 of the Jumpstart our Business Startups Act (JOBS Act) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2015. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

Use of Estimates   The preparation of the Companys financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.

Cash, Cash Equivalents, and Short-Term Investments   The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.

Concentration of Credit Risk   Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At March 31, 2016, the Company has no uninsured cash balances.

Fair Value of Financial Instruments   In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.

Fair Value Measurements   The ASC Topic 820, Fair Value Measurements, defines fair value, establishes a framework for measuring fair value in accordance with U.S. generally accepted accounting principles, and requires certain disclosures about fair value measurements. In general, fair values of financial instruments are based upon quoted market prices, where available. If such quoted market prices are not available, fair value is based upon internally developed models that primarily use, as inputs, observable market-based parameters. Valuation adjustments may be made to ensure that financial instruments are recorded at fair value. These adjustments may include amounts to reflect counterparty credit quality and the customers creditworthiness, among other things, as well as unobservable parameters. Any such valuation adjustments are applied consistently over time.

Property and Equipment   Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the quarters ended March 31, 2016 and March 31, 2015 was $547 and $668, respectively.

Intangible Assets   Costs incurred to acquire and/or develop the Companys product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of seven to sixteen years. Intangible assets are stated at the lower of cost or estimated fair market value. During the quarters ended March 31, 2016 and March 31, 2015, the Company did not capitalize any such costs. (See Note 10). Amortization expense for the quarters ended March 31, 2016 and March 31, 2015 was $0 and $148,059, respectively.

Impairment of Long-Lived Assets   The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, Property, Plant and Equipment. If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value. No impairment losses were recognized for the quarters ended March 31, 2016 and March 31, 2015.

Research and Development Costs   Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Companys behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.

Income Taxes   The Company follows FASB ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.   The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of December 31, 2015, and 2014, the Company does not have a liability for unrecognized tax uncertainties.   The Companys policy is to record interest and penalties on uncertain tax positions as income tax expense. At the end of the quarters ended March 31, 2016 and March 31, 2015, the Company had not accrued any interest or penalties related to uncertain tax positions.

Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration   The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Companys common stock at the date of the agreement.   The Companys accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, Equity-Based Payments to Non-Employees. The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendors performance is complete.

Non-controlling Interest   In accordance with ASC 810, Consolidation, the Company consolidates Cytocom, Inc. The non-controlling interests in Cytocom represent the interests of outside shareholders in the equity and results of operations of Cytocom.

Net Loss per Share   Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Companys net loss position.   A calculation of basic and diluted net loss per share follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">For the three months ended March 31,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Historical net loss per share:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Numerator</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%; line-height: 115%">Net loss</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(6,645,402</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 11%; text-align: right; line-height: 115%">(2,905,406</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Non-controlling interest</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(44,120</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(124,065</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Net loss attributed to Common stockholders</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(6,601,282</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(2,781,341</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Denominator</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 115%">Weighted-average common shares outstandingDenominator for basic and diluted net loss per share</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">190,923,381</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">138,795,044</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 115%">Basic and diluted net loss per share attributed to common stockholders</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(0.03</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(0.02</td> <td style="line-height: 115%">)</td></tr> </table>   The Companys potential dilutive securities which include stock and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common stock outstanding used to calculate both basic and diluted net loss per share is the same.   The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">For the three months ended March 31,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Warrants to purchase Common stock</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">24,731,500</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">9,372,750</td> <td style="line-height: 115%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>

Recent Accounting Standards   During the quarter ended March 31, 2016, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Companys consolidated financial statements.

206913301

250000

40000

5000

1314169

1712876

0.00

66500000

expire in 2032-2035.

100000

198312

200000

961250

120000

245000

1786285

450000 500000

Under the agreement, the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment.

By either party upon provision of written notice at least 90 days before the end of the agreement, provided however that if the Company terminates the contract without cause it will be required to pay ViPharma a $10 million penalty.

EX-101.SCH 5 imnp-20160331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stock Compensation link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Income Taxes - Results of Operations link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Licenses and Supply Agreements link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Organization and Description of Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants - Summary of Outstanding Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Stock Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Income Taxes - Results of Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Licenses and Supply Agreements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 imnp-20160331_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 imnp-20160331_def.xml XBRL DEFINITION FILE EX-101.LAB 8 imnp-20160331_lab.xml XBRL LABEL FILE Common Stock [Member] Equity Components [Axis] Additional Paid-In Capital [Member] Stock To Be Issued [Member] Prepaid Service [Member] Accumulated Deficit [Member] Non-controlling Interest [Member] Cytocom Inc., [Member] Legal Entity [Axis] Irish Limited Liability [Member] Notes Payable One [Member] Debt Instrument [Axis] Notes Payable Two [Member] Notes Payable Three [Member] Notes Payable Four [Member] Notes Payable Five [Member] Notes Payable Six [Member] Notes Payable Seven [Member] Notes Payable Eight [Member] Ira Gaines [Member] Related Party [Axis] Lenders [Member] Roger Bozarth [Member] Minimum [Member] Range [Axis] Maximum [Member] Lenders [Member] Robert J. Dailey [Member] Lender [Member] Lender [Member] Warrant [Member] Second Quarter 2016 [Member] Class of Warrant or Right [Axis] Third Quarter 2016 [Member] Third Quarter 2017 [Member] Fourth Quarter 2017 [Member] First Quarter 2018 [Member] Second Quarter 2018 [Member] Third Quarter 2018 [Member] Fourth Quarter 2018 [Member] First Quarter 2019 [Member] Second Quarter 2019 [Member] Third Quarter 2019 [Member] Fourth Quarter 2019 [Member] Second Quarter 2020 [Member] TNI BioTech IP, Inc. [Member] Business Acquisition [Axis] Dr. Plotnikoff [Member] TNI IP’s Management [Member] Young Agreement [Member] Agreement [Axis] Dr. Bernard Bihari [Member] Smith Agreement [Member] Initial License Fee [Member] Scenario [Axis] Expenses [Member] Shan Agreement [Member] GBOIG [Member] Distribution Agreements In Nigeria [Member] AHAR Pharma [Member] Agreements With Hubei Qianjiang Pharmaceutical Company [Member] Plaintiff Claims [Member] Other Commitments [Axis] Plaintiff EK Krause & Associates [Member] Webfoot, Inc [Member] Noreen Griffin [Member] Griffin Enterprises, Inc [Member] Ms. Wilson [Member] Pixelheads, Inc. [Member] Notes Payable Nine [Member] Notes Payable Ten [Member] Second Quarter 2021 [Member] Orlando, Florida [Member] Lease Arrangement, Type [Axis] May 15, 2016 [Member] Report Date [Axis] Mr. Wilson [Member] Title of Individual [Axis] Subsequent Event [Member] Subsequent Event Type [Axis] Agreements With Hubei Qianjiang Pharmaceutical Company [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and cash equivalents Accounts receivable Prepaids and other current assets Total current assets Fixed Assets: Computer equipment, net of accumulated depreciation of $6,878 and $6,331 respectively Deposits Total assets LIABILITIES AND STOCKHOLDERS’ DEFICIT Current Liabilities: Accounts payable Accrued liabilities Current portion of notes payable Total current liabilities Total liabilities Commitments and contingencies (Note 11) Stockholders’ Deficit: Common stock - par value $0.0001; 500,000,000 shares authorized; 205,127,530 and 174,850,047 shares issued and outstanding respectively Additional paid in capital Stock issuances due Prepaid services Accumulated deficit Equity attributable to common stockholders Non-controlling interest Total stockholders’ deficit Total liabilities and stockholders’ deficit Accumulated depreciation Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Shares Issued Common Stock, Shares Outstanding Income Statement [Abstract] Revenues, net Operating expenses: Selling, general and administrative Research and development expense Stock issued for services G&A Stock issued for services R&D Warrant valuation expense Depreciation and amortization expense Total operating expenses Loss from operations Other income (expense): Interest expense Loss on settlement of debt Total other income (expense) Net loss Net loss attributable to non-controlling interest Net loss attributable to common shareholders Basic and diluted loss per share to common shareholders Weighted average number of shares outstanding Statement [Table] Statement [Line Items] Balance Balance, shares Issuance of common stock for prepaid services Issuance of common stock for prepaid services, shares Amortization of prepaid services Issuance of common stock in exchange for debt Issuance of common stock in exchange for debt, shares Issuance of common stock for cash and exercise of warrants Issuance of common stock for cash and exercise of warrants, shares Issuance of common stock warrants Net loss Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash flows used in operating activities: Depreciation Amortization Amortization of stock issued for prepaid services Stock issued for services Stock warrant expense Loss on settlement of debt Changes in operating assets and liabilities: Accounts receivable Accounts payable Accrued liabilities Prepaid expenses and other current assets Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from sale of stock and exercise of warrants Proceeds from issuance of notes payable Net cash provided by financing activities Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Cash paid for interest SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Issuance of common stock in exchange for debt and accrued interest Accounting Policies [Abstract] Organization and Description of Business Summary of Significant Accounting Policies Property, Plant and Equipment [Abstract] Property and Equipment EX-101.PRE 9 imnp-20160331_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	May. 12, 2016
Document And Entity Information
Entity Registrant Name	Immune Therapeutics, Inc.
Entity Central Index Key	0001559356
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		206,913,301
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2016

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 132,817	$ 23,149
Accounts receivable	19,660	$ 16,197
Prepaids and other current assets	1,594
Total current assets	153,441	$ 39,346
Fixed Assets:
Computer equipment, net of accumulated depreciation of $6,878 and $6,331 respectively	1,135	1,682
Deposits	200	200
Total assets	154,776	41,228
Current Liabilities:
Accounts payable	1,860,361	1,924,672
Accrued liabilities	1,641,351	1,281,039
Current portion of notes payable	2,838,200	2,793,701
Total current liabilities	6,339,912	5,999,412
Total liabilities	6,339,912	5,999,412
Stockholders’ Deficit:
Common stock - par value $0.0001; 500,000,000 shares authorized; 205,127,530 and 174,850,047 shares issued and outstanding respectively	20,513	17,485
Additional paid in capital	351,290,136	343,434,786
Stock issuances due	1,173,244	1,140,303
Prepaid services	(2,133,286)	(660,417)
Accumulated deficit	(354,391,171)	(347,789,889)
Equity attributable to common stockholders	(4,040,564)	(3,857,732)
Non-controlling interest	(2,144,572)	(2,100,452)
Total stockholders’ deficit	(6,185,136)	(5,958,184)
Total liabilities and stockholders’ deficit	$ 154,776	$ 41,228

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 6,878	$ 6,331
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares Issued	205,127,530	174,850,047
Common Stock, Shares Outstanding	205,127,530	174,850,047

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenues, net	$ 3,463	$ 2,070
Operating expenses:
Selling, general and administrative	939,341	401,988
Research and development expense	(18,842)	177,157
Stock issued for services G&A	$ 1,983,837	$ 2,161,559
Stock issued for services R&D
Warrant valuation expense	$ 2,078,199
Depreciation and amortization expense	547	$ 148,727
Total operating expenses	4,983,082	2,889,431
Loss from operations	(4,979,619)	(2,887,361)
Other income (expense):
Interest expense	(301,444)	$ (18,045)
Loss on settlement of debt	(1,364,339)
Total other income (expense)	(1,665,783)	$ (18,045)
Net loss	(6,645,402)	(2,905,406)
Net loss attributable to non-controlling interest	(44,120)	(124,065)
Net loss attributable to common shareholders	$ (6,601,282)	$ (2,781,341)
Basic and diluted loss per share to common shareholders	$ (0.03)	$ (0.02)
Weighted average number of shares outstanding	190,923,381	138,795,044

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited) - 3 months ended Mar. 31, 2016 - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Stock To Be Issued [Member]	Prepaid Service [Member]	Accumulated Deficit [Member]	Non-controlling Interest [Member]	Total
Balance at Dec. 31, 2015	$ 17,485	$ 343,434,786	$ 1,140,303	$ (660,417)	$ (347,789,889)	$ (2,100,452)	$ (5,958,184)
Balance, shares at Dec. 31, 2015	174,850,047
Issuance of common stock for prepaid services	$ 1,904	$ 3,724,266	$ (269,466)	(2,142,535)			1,314,169
Issuance of common stock for prepaid services, shares	19,043,000
Amortization of prepaid services				$ 669,667			669,667
Issuance of common stock in exchange for debt	$ 1,093	$ 2,027,915	$ 277,407				2,306,415
Issuance of common stock in exchange for debt, shares	10,921,983
Issuance of common stock for cash and exercise of warrants	$ 31	24,969	$ 25,000				50,000
Issuance of common stock for cash and exercise of warrants, shares	312,500
Issuance of common stock warrants		$ 2,078,199					2,078,199
Net loss					$ (6,601,282)	$ (44,120)	(6,645,402)
Balance at Mar. 31, 2016	$ 20,513	$ 351,290,136	$ 1,173,244	$ (2,133,286)	$ (354,391,171)	$ (2,144,572)	$ (6,185,136)
Balance, shares at Mar. 31, 2016	205,127,530

XML 15 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (6,645,402)	$ (2,905,406)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	$ 547	668
Amortization		148,060
Amortization of stock issued for prepaid services	$ 669,667	$ 2,161,559
Stock issued for services	1,314,169
Stock warrant expense	2,078,199
Loss on settlement of debt	1,364,339
Changes in operating assets and liabilities:
Accounts receivable	(3,463)	$ (2,070)
Accounts payable	139,203	(192,521)
Accrued liabilities	486,373	$ 32,600
Prepaid expenses and other current assets	(1,594)
Net cash used in operating activities	$ (597,962)	$ (757,110)
CASH FLOWS FROM INVESTING ACTIVITIES
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of stock and exercise of warrants	$ 50,000	$ 95,000
Proceeds from issuance of notes payable	657,000	500,975
Net cash provided by financing activities	707,000	595,975
Net decrease in cash and cash equivalents	109,038	(161,135)
Cash and cash equivalents at beginning of period	23,149	191,987
Cash and cash equivalents at end of period	132,817	30,852
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	7,050	$ 4,500
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock in exchange for debt and accrued interest	$ 2,306,415

XML 16 R7.htm IDEA: XBRL DOCUMENT

Organization and Description of Business

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Organization and Description of Business

1. Organization and Description of Business

Going Concern

XML 17 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Cash, Cash Equivalents, and Short-Term Investments

Concentration of Credit Risk

Fair Value of Financial Instruments

Fair Value Measurements

Property and Equipment

Intangible Assets

Impairment of Long-Lived Assets

Research and Development Costs

Income Taxes

Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration

Non-controlling Interest

Net Loss per Share

A calculation of basic and diluted net loss per share follows:

	For the three months ended March 31,
	2016			2015
Historical net loss per share:
Numerator
Net loss	$	(6,645,402	)	$	(2,905,406	)
Non-controlling interest		(44,120	)		(124,065	)
Net loss attributed to Common stockholders	$	(6,601,282	)	$	(2,781,341	)

Denominator
Weighted-average common shares outstanding—Denominator for basic and diluted net loss per share		190,923,381			138,795,044
Basic and diluted net loss per share attributed to common stockholders	$	(0.03	)	$	(0.02	)

	For the three months ended March 31,
	2016		2015
Warrants to purchase Common stock		24,731,500		9,372,750

Recent Accounting Standards

XML 18 R9.htm IDEA: XBRL DOCUMENT

Property and Equipment

3 Months Ended

Mar. 31, 2016

Fixed Assets:

Property and Equipment

3. Property and Equipment

	March 31, 2016			December 31, 2015
Property and equipment:
Computer equipment	$	8,013		$	8,013

Less accumulated depreciation		(6,878	)		(6,331	)
Property and equipment, net	$	1,135		$	1,682

The Company utilizes the straight-line method for depreciation, using three to five-year depreciable asset lives. Depreciation expense was not material for all periods presented.

XML 19 R10.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

3 Months Ended

Mar. 31, 2016

Payables and Accruals [Abstract]

Accrued Liabilities

4. Accrued Liabilities

Accrued expenses and other liabilities consist of the following:

	March 31, 2016		December 31, 2015
	(in thousands)
Accrued payroll to officers and others	$	1,077,640	$	758,342
Accrued interest - notes payable		365,006		236,671
Estimated legal settlement		198,312		282,136
Other accrued liabilities		393		323
State payroll taxes		-		3,567
Total accrued expenses and other liabilities	$	1,641,351	$	1,281,039

XML 20 R11.htm IDEA: XBRL DOCUMENT

Notes Payable

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Notes Payable

5. Notes Payable

Notes payable consist of the following:

	March 31, 2016			December 31, 2015
Promissory note issued July 29, 2014 to Ira Gaines. The note matures on January 27, 2015 and earns interest at a rate of 18% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender.	$	100,000		$	100,000

Promissory notes issued between November 26, 2014 and September 30, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $346,000 were in default at March 31, 2016, as the Company was unable to pay installments on those notes on their due dates. No demands for repayment have been made by the lenders. In the quarter ended March 31, 2016, $365,500 of these notes and their accompanying interest were converted into 5,191,909 shares of Immune Therapeutics common stock.		346,000			711,500

Promissory note issued October 17, 2014 to Roger Bozarth. The note matures on October 17, 2015 and earns interest at a rate of 2% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. In the quarter ended March 31, 2016, this note and the accompanying interest was converted into 89,639 shares of Immune Therapeutics common stock.		-			7,000

Promissory notes issued between May 1, 2015 and September 30, 2015, and maturing between June 14, 2015 and December 31, 2015. Lenders on loans aggregating $356,432 earn interest at rates between 10% and 18% per annum. On loans aggregating $223,500, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $223,500 were in default at March 31, 2016, as the Company was unable to repay those notes on their due dates. No demands for repayment have been made by the lenders. In the quarter ended March 31, 2016, $140,001 of these notes and their accompanying interest were converted into 2,420,377 shares of Immune Therapeutics common stock.		579,932			669,933

Promissory note issued January 26, 2015 to Robert J. Dailey. The note is senior to, and has priority in right of payment over, all indebtedness of the Company. The note earns interest at a rate of 2% per annum and was due on July 30, 2015. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender.		200,000			200,000

Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on September 30, 2016.		750,000			800,000

Promissory notes issued in December 2015. Lenders earn interest at a rate of 10% per month. Notes are repayable on March 9, 2016. The Company was unable to repay the note at maturity and the note is in default. The Company is obligated to pay late-payment penalties totaling $6,667 per day.		130,000			130,000

Promissory note issued November 24, 2015 as settlement of amounts owing to a law firm. The Lender earns interest at the rate of 10% per annum. The note is repayable in full on December 1, 2016.		175,268			175,268

Promissory notes issued between January 1, 2016 and March 31, 2016. Lenders earn interest at a rate of 10% per month. Notes are repayable in one year.		312,000

Promissory note issued February 3, 2016, payable in 90 days which includes an original issue discount of $40,000 and expenses of $5,000, resulting in net proceeds of $200,000.		245,000

Total		2,838,200			2,793,701

Less: Current Portion		(2,838,200	)		(2,793,701	)

Long-Term debt, less current portion	$	-		$	-

As of March 31, 2016, the Company had accrued $365,006 in unpaid interest, compared to $236,671 as of December 31, 2015

XML 21 R12.htm IDEA: XBRL DOCUMENT

Capital Structure - Common Stock and Common Stock Purchase Warrants

3 Months Ended

Mar. 31, 2016

Notes to Financial Statements

Capital Structure - Common Stock and Common Stock Purchase Warrants

6. Capital Structure—Common Stock and Common Stock Purchase Warrants

As of March 31, 2016 and 2015, the Company was authorized to issue 500,000,000 common shares at a par value of $0.0001 per share.

As of March 31, 2016, the Company had 205,127,530 shares of common stock outstanding and 178,850,047 outstanding as of December 31, 2015.

Stock Warrants

In the quarter ended March 31, 2016, the Company issued 15,600,000 warrants.

There were no modifications of the terms of any warrants issued by the Company in the quarters ended March 31, 2016 and 2015.

Following is a summary of outstanding stock warrants at March 31, 2016 and activity during the three months then ended:

	Number of Shares		Exercise Price		Weighted Average Price
Warrants as of December 31, 2015		9,131,500	$	0.07-15.00	$	1.47

Issued in 2016		15,600,000	$	.020-2.00	$	0.39

Expired		-	$	-	$	-

Exercised		-	$	-	$	-

Warrants as of March 31, 2016		24,731,500	$	0.07-15.00	$	0.79

Summary of outstanding warrants as of March 31, 2016:

Expiration Date	Number of Shares		Exercise Price		Remaining Life (years)
Second Quarter 2016		37,500	$	5.00		.25
Third Quarter 2016		525,000	$	1.00-5.00		.50
Third Quarter 2017		1,500,000	$	1.00		1.50
Fourth Quarter 2017		2,941,666	$	1.00-9.00		1.75
First Quarter 2018		127,500	$	15.00		2.00
Second Quarter 2018		33,334	$	15.00		2.25
Third Quarter 2018		650,000	$	1.00-1.50		2.50
Fourth Quarter 2018		1,197,500	$	1.00-1.50		2.75
First Quarter 2019		4,024,000	$	0.50-2.00		3.00
Second Quarter 2019		135,000	$	0.07–0.23		3.25
Third Quarter 2019		260,000	$	0.50		3.50
Fourth Quarter 2019		400,000	$	0.14		3.75
Second Quarter 2020		300,000	$	0.50		4.25
First Quarter 2021		12,600,000	$	0.20		5.00

XML 22 R13.htm IDEA: XBRL DOCUMENT

Stock Compensation

3 Months Ended

Mar. 31, 2016

Equity [Abstract]

Stock Compensation

7. Stock Compensation

Shares Issued for Services

XML 23 R14.htm IDEA: XBRL DOCUMENT

Income Taxes - Results of Operations

3 Months Ended

Mar. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes - Results of Operations

8. Income Taxes - Results of Operations

There was no income tax expense reflected in the results of operations for the quarters ended March 31, 2016 and 2015 because the Company incurred a net loss in both quarters.

As of December 31, 2015, we have estimated federal and state income tax net operating loss (“NOL”) carry-forwards of approximately $66,500,000, which will expire in 2032-2035.

XML 24 R15.htm IDEA: XBRL DOCUMENT

Licenses and Supply Agreements

3 Months Ended

Mar. 31, 2016

Notes to Financial Statements

Licenses and Supply Agreements

9. Licenses and Supply Agreements

Patent and Subsidiary Acquisition

Patent License Agreements

XML 25 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. Commitments and Contingencies

Malawi Treatment Facilities

a.	The first protocol, submitted jointly with The Jack Brewer Foundation (“JBF Worldwide”), received PMPB approval on November 11, 2015. The protocol covers a 12-month trial for a “Single Visit Approach to Cervical Cancer Prevention.” The approach is designed to deliver a preventive and simple procedure that can be performed in a clinical setting without the use of a laboratory and to allow for immediate treatment of any precancerous lesions utilizing Wallach LL100 Cryosurgical systems. The protocol provides for 50% of the patient group to be put on Lodonal™ to determine if the drug lowers the number of opportunistic infections during the year, and if it can be shown that LDN increases CD4, CE8, NK and T cell count, which would show that the incidence rates of opportunistic infection could decrease with Lodonal™ and that Lodonal™ could be used as a prophylaxis to prevent substantial HIV-related morbidity in Malawi. The final trial agreement with PMPB was signed in February 2016. Lodonal™ pills have been produced in Nicaragua in anticipation of the trial. Shipments will commence once the trial is approved.

b.	The second protocol, which has not yet been approved, covers a trial using Lodonal™ for the treatment of cancer.

Open an Oncology and Infectious Disease Center in Malawi at Queen Elizabeth Central Hospital

Distribution Agreements in Nigeria

Agreements with Hubei Qianjiang Pharmaceutical Company

Exploratory Toxicology (nGLP)

-Dose range finding studies

- Different species and methods of administration

- Multiple dosing regimens

- Estimate the response vs. dose given

Definitive Toxicology (GLP)

- Performed in collaboration with Calvert Laboratories (USA) and MPI/Medicillon (China)

- General toxicology studies

- Different species and methods of administration

- Immunogenicity study with NHPs

Special Toxicology Studies (planned)

Supervision and Inspection of Manufacturing in Nicaragua

Operating Leases

Legal Proceedings

XML 26 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2016

Subsequent Events [Abstract]

Subsequent Events

11. Subsequent Events

On May 9, 2016, the Company and KRS Global Bio Technology, Inc. mutually agreed to terminate their Contract for the Compounding of Pharmaceutical Products dated December 8, 2014.

Between March 31, 2016 and May 16, 2016 the Company issued promissory notes aggregating $961,250 and paid off notes totaling $245,000.

As of May 16, 2016, the Company had outstanding 206,913,301 shares of common stock.

XML 27 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2016

Summary Of Significant Accounting Policies Policies

Basis of Presentation

Basis of Presentation

Use of Estimates

Use of Estimates

Cash, Cash Equivalents, and Short-term Investments

Cash, Cash Equivalents, and Short-Term Investments

Concentration of Credit Risk

Concentration of Credit Risk

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Fair Value Measurements

Fair Value Measurements

Property and Equipment

Property and Equipment

Intangible Assets

Intangible Assets

Impairment of Long-lived Assets

Impairment of Long-Lived Assets

Research and Development Costs

Research and Development Costs

Income Taxes

Income Taxes

Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration

Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration

Non-controlling Interest

Non-controlling Interest

Net Loss Per Share

Net Loss per Share

A calculation of basic and diluted net loss per share follows:

	For the three months ended March 31,
	2016			2015
Historical net loss per share:
Numerator
Net loss	$	(6,645,402	)	$	(2,905,406	)
Non-controlling interest		(44,120	)		(124,065	)
Net loss attributed to Common stockholders	$	(6,601,282	)	$	(2,781,341	)

Denominator
Weighted-average common shares outstanding—Denominator for basic and diluted net loss per share		190,923,381			138,795,044
Basic and diluted net loss per share attributed to common stockholders	$	(0.03	)	$	(0.02	)

	For the three months ended March 31,
	2016		2015
Warrants to purchase Common stock		24,731,500		9,372,750

Recent Accounting Standards

Recent Accounting Standards

XML 28 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2016

Summary Of Significant Accounting Policies Tables

Schedule of Basic and Diluted Net Loss Per Share

A calculation of basic and diluted net loss per share follows:

	For the three months ended March 31,
	2016			2015
Historical net loss per share:
Numerator
Net loss	$	(6,645,402	)	$	(2,905,406	)
Non-controlling interest		(44,120	)		(124,065	)
Net loss attributed to Common stockholders	$	(6,601,282	)	$	(2,781,341	)

Denominator
Weighted-average common shares outstanding—Denominator for basic and diluted net loss per share		190,923,381			138,795,044
Basic and diluted net loss per share attributed to common stockholders	$	(0.03	)	$	(0.02	)

Schedule of Antidilutive Securities

	For the three months ended March 31,
	2016		2015
Warrants to purchase Common stock		24,731,500		9,372,750

XML 29 R20.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2016

Property And Equipment Tables

Schedule of Property and Equipment

	March 31, 2016			December 31, 2015
Property and equipment:
Computer equipment	$	8,013		$	8,013

Less accumulated depreciation		(6,878	)		(6,331	)
Property and equipment, net	$	1,135		$	1,682

XML 30 R21.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2016

Accrued Liabilities Tables

Schedule of Accrued Liabilities

Accrued expenses and other liabilities consist of the following:

	March 31, 2016		December 31, 2015
	(in thousands)
Accrued payroll to officers and others	$	1,077,640	$	758,342
Accrued interest - notes payable		365,006		236,671
Estimated legal settlement		198,312		282,136
Other accrued liabilities		393		323
State payroll taxes		-		3,567
Total accrued expenses and other liabilities	$	1,641,351	$	1,281,039

XML 31 R22.htm IDEA: XBRL DOCUMENT

Notes Payable (Tables)

3 Months Ended

Mar. 31, 2016

Notes Payable Tables

Schedule of Notes Payable

Notes payable consist of the following:

	March 31, 2016			December 31, 2015
Promissory note issued July 29, 2014 to Ira Gaines. The note matures on January 27, 2015 and earns interest at a rate of 18% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender.	$	100,000		$	100,000

Promissory notes issued between November 26, 2014 and September 30, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $346,000 were in default at March 31, 2016, as the Company was unable to pay installments on those notes on their due dates. No demands for repayment have been made by the lenders. In the quarter ended March 31, 2016, $365,500 of these notes and their accompanying interest were converted into 5,191,909 shares of Immune Therapeutics common stock.		346,000			711,500

Promissory note issued October 17, 2014 to Roger Bozarth. The note matures on October 17, 2015 and earns interest at a rate of 2% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. In the quarter ended March 31, 2016, this note and the accompanying interest was converted into 89,639 shares of Immune Therapeutics common stock.		-			7,000

Promissory notes issued between May 1, 2015 and September 30, 2015, and maturing between June 14, 2015 and December 31, 2015. Lenders on loans aggregating $356,432 earn interest at rates between 10% and 18% per annum. On loans aggregating $223,500, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $223,500 were in default at March 31, 2016, as the Company was unable to repay those notes on their due dates. No demands for repayment have been made by the lenders. In the quarter ended March 31, 2016, $140,001 of these notes and their accompanying interest were converted into 2,420,377 shares of Immune Therapeutics common stock.		579,932			669,933

Promissory note issued January 26, 2015 to Robert J. Dailey. The note is senior to, and has priority in right of payment over, all indebtedness of the Company. The note earns interest at a rate of 2% per annum and was due on July 30, 2015. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender.		200,000			200,000

Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on September 30, 2016.		750,000			800,000

Promissory notes issued in December 2015. Lenders earn interest at a rate of 10% per month. Notes are repayable on March 9, 2016. The Company was unable to repay the note at maturity and the note is in default. The Company is obligated to pay late-payment penalties totaling $6,667 per day.		130,000			130,000

Promissory note issued November 24, 2015 as settlement of amounts owing to a law firm. The Lender earns interest at the rate of 10% per annum. The note is repayable in full on December 1, 2016.		175,268			175,268

Promissory notes issued between January 1, 2016 and March 31, 2016. Lenders earn interest at a rate of 10% per month. Notes are repayable in one year.		312,000

Promissory note issued February 3, 2016, payable in 90 days which includes an original issue discount of $40,000 and expenses of $5,000, resulting in net proceeds of $200,000.		245,000

Total		2,838,200			2,793,701

Less: Current Portion		(2,838,200	)		(2,793,701	)

Long-Term debt, less current portion	$	-		$	-

XML 32 R23.htm IDEA: XBRL DOCUMENT

Capital Structure - Common Stock and Common Stock Purchase Warrants (Tables)

3 Months Ended

Mar. 31, 2016

Capital Structure - Common Stock And Common Stock Purchase Warrants Tables

Schedule of Outstanding Stock Warrants

Following is a summary of outstanding stock warrants at March 31, 2016 and activity during the three months then ended:

	Number of Shares		Exercise Price		Weighted Average Price
Warrants as of December 31, 2015		9,131,500	$	0.07-15.00	$	1.47

Issued in 2016		15,600,000	$	.020-2.00	$	0.39

Expired		-	$	-	$	-

Exercised		-	$	-	$	-

Warrants as of March 31, 2016		24,731,500	$	0.07-15.00	$	0.79

Summary of Outstanding Warrants

Summary of outstanding warrants as of March 31, 2016:

Expiration Date	Number of Shares		Exercise Price		Remaining Life (years)
Second Quarter 2016		37,500	$	5.00		.25
Third Quarter 2016		525,000	$	1.00-5.00		.50
Third Quarter 2017		1,500,000	$	1.00		1.50
Fourth Quarter 2017		2,941,666	$	1.00-9.00		1.75
First Quarter 2018		127,500	$	15.00		2.00
Second Quarter 2018		33,334	$	15.00		2.25
Third Quarter 2018		650,000	$	1.00-1.50		2.50
Fourth Quarter 2018		1,197,500	$	1.00-1.50		2.75
First Quarter 2019		4,024,000	$	0.50-2.00		3.00
Second Quarter 2019		135,000	$	0.07–0.23		3.25
Third Quarter 2019		260,000	$	0.50		3.50
Fourth Quarter 2019		400,000	$	0.14		3.75
Second Quarter 2020		300,000	$	0.50		4.25
First Quarter 2021		12,600,000	$	0.20		5.00

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 33 R24.htm IDEA: XBRL DOCUMENT

Organization and Description of Business (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		12 Months Ended
	Dec. 08, 2014	Mar. 31, 2014	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Net loss			$ 6,645,402	$ 2,905,406
Cash equivalents			497,962
Stockholders equity			$ 6,185,136		$ 5,958,184
Cytocom Inc., [Member]
Number of shares issued druing period	113,242,522				140,100,000
Percentage of stake issued during period	55.30%				50.20%
Irish Limited Liability [Member]
Percentage of low corporate income tax rate		12.50%

XML 34 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Summary Of Significant Accounting Policies Details Narrative
Maximum of annual gross revenue			$ 1,000,000,000
Federal deposit insurance corporation value	$ 250,000
Depreciation expense	547	$ 668
Amortization expense	$ 0	$ 148,059
Impairment loss

XML 35 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Summary Of Significant Accounting Policies - Schedule Of Basic And Diluted Net Loss Per Share Details
Numerator, Net loss	$ (6,645,402)	$ (2,905,406)
Numerator, Non-controlling interest	(44,120)	(124,065)
Numerator, Net loss attributed to Common stockholders	$ (6,601,282)	$ (2,781,341)
Denominator, Weighted-average common shares outstanding-Denominator for basic and diluted net loss per share	190,923,381	138,795,044
Denominator, Basic and diluted net loss per share attributed to common stockholders	$ (0.03)	$ (0.02)

XML 36 R27.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Summary Of Significant Accounting Policies - Schedule Of Basic And Diluted Net Loss Per Share Details
Warrants to purchase Common stock	24,731,500	9,372,750

XML 37 R28.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Narrative)	3 Months Ended
Property and Equipment (Details Narrative)	Mar. 31, 2016
Property And Equipment Details Narrative
Depreciable asset lives	5 years

XML 38 R29.htm IDEA: XBRL DOCUMENT

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Property And Equipment - Schedule Of Property And Equipment Details
Computer equipment	$ 8,013	$ 8,013
Less accumulated depreciation	(6,878)	(6,331)
Property and equipment, net	$ 1,135	$ 1,682

XML 39 R30.htm IDEA: XBRL DOCUMENT

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Accrued Liabilities - Schedule Of Accrued Liabilities Details
Accrued payroll to officers and others	$ 1,077,640,000	$ 758,342,000
Accrued interest - notes payable	365,006,000	236,671,000
Estimated legal settlement	198,312,000	282,136,000
Other accrued liabilities	$ 393,000	323,000
State payroll taxes		3,567,000
Total accrued expenses and other liabilities	$ 1,641,351,000	$ 1,281,039,000

XML 40 R31.htm IDEA: XBRL DOCUMENT

Notes Payable (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
Notes Payable (Details Narrative) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Notes Payable Details Narrative
Accrued unpaid interest	$ 365,006	$ 236,671

XML 41 R32.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Total	$ 2,838,200	$ 2,793,701
Less: Current portion	(2,838,200)	(2,793,701)
Notes Payable One [Member]
Total	100,000	100,000
Notes Payable Two [Member]
Total	$ 346,000	711,500
Notes Payable Three [Member]
Total		7,000
Notes Payable Four [Member]
Total	$ 579,932	669,933
Notes Payable Five [Member]
Total	200,000	200,000
Notes Payable Six [Member]
Total	750,000	800,000
Notes Payable Seven [Member]
Total	130,000	130,000
Notes Payable Eight [Member]
Total	175,268	$ 175,268
Notes Payable Nine [Member]
Total	312,000
Notes Payable Ten [Member]
Total	$ 245,000

XML 42 R33.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical)						1 Months Ended	3 Months Ended		10 Months Ended	12 Months Ended
	Feb. 03, 2016 USD ($)	Nov. 24, 2015	Jan. 26, 2015	Oct. 17, 2014	Jul. 29, 2014	Dec. 31, 2015 USD ($)	Mar. 31, 2016 USD ($) shares	Mar. 31, 2015	Sep. 30, 2015 USD ($) Installments	Dec. 31, 2015 USD ($) shares
Percentage of interest rate per annum							10.00%		10.00%
Maximum amount raise in debt									$ 2,000,000
Number of installments, months \| Installments									36
Original issue discount	$ 40,000
Debt issuance cost	5,000
Net proceeds from notes payable	$ 200,000
Cytocom Inc., [Member]
Note matures date								Sep. 30, 2016
Minimum [Member] \| Cytocom Inc., [Member]
Percentage of interest rate per annum							5.00%
Maximum [Member] \| Cytocom Inc., [Member]
Percentage of interest rate per annum							10.00%
Ira Gaines [Member]
Note matures date					Jan. 27, 2015
Percentage of interest rate per annum					18.00%
Lenders [Member]
Notes aggregating default amount							$ 346,000
Value of notes that converted into shares							$ 365,500
Notes and interest converted into shares \| shares							5,191,909
Aggregating loan									$ 356,432
Interest payable									$ 223,500
Lenders [Member] \| Minimum [Member]
Percentage of interest rate per annum									10.00%
Lenders [Member] \| Maximum [Member]
Percentage of interest rate per annum									18.00%
Roger Bozarth [Member]
Note matures date				Oct. 17, 2015
Percentage of interest rate per annum				2.00%
Notes and interest converted into shares \| shares							89,639
Lenders [Member]
Maximum amount raise in debt							$ 140,001
Notes aggregating default amount							$ 223,500
Notes and interest converted into shares \| shares										2,420,377
Robert J. Dailey [Member]
Note matures date			Jul. 30, 2015
Percentage of interest rate per annum			2.00%
Lender [Member]
Note matures date						Mar. 09, 2016
Percentage of interest rate per annum						10.00%				10.00%
Pay late-payment penalties per day						$ 6,667				$ 6,667
Lender [Member]
Note matures date		Dec. 01, 2016
Percentage of interest rate per annum		10.00%

XML 43 R34.htm IDEA: XBRL DOCUMENT

Capital Structure - Common Stock and Common Stock Purchase Warrants (Details Narrative) - $ / shares	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Capital Structure - Common Stock And Common Stock Purchase Warrants Details Narrative
Common Stock, Par Value	$ 0.0001	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	500,000,000	500,000,000	500,000,000
Common Stock, Shares Issued	205,127,530	174,850,047
Common Stock, Shares Outstanding	205,127,530	174,850,047
Number of warrants issued during period	15,600,000

XML 44 R35.htm IDEA: XBRL DOCUMENT

Capital Structure - Common Stock and Common Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details) - Warrant [Member]	3 Months Ended
	Mar. 31, 2016 $ / shares shares
Warrants, Number of shares Beginning balance \| shares	9,131,500
Warrants, Number of shares Issued \| shares	15,600,000
Warrants, Number of shares Expired \| shares
Warrants, Number of shares Exercised \| shares
Warrants, Number of shares Ending balance \| shares	24,731,500
Exercise Price, Expired	$ 1.50
Exercise Price, Exercised	.50
Weighted average exercise price, Beginning balance	1.47
Weighted average exercise price, Issued	$ 0.39
Weighted average exercise price, Expired
Weighted average exercise price, Exercised
Weighted average exercise price, Ending balance	$ 0.79
Minimum [Member]
Exercise Price, Beginning balance	0.07
Exercise Price, Issued	0.20
Exercise Price, Ending balance	0.07
Maximum [Member]
Exercise Price, Beginning balance	15.00
Exercise Price, Issued	.50
Exercise Price, Ending balance	$ 15.00

XML 45 R36.htm IDEA: XBRL DOCUMENT

Capital Structure - Common Stock and Common Stock Purchase Warrants - Summary of Outstanding Warrants (Details)	3 Months Ended
	Mar. 31, 2016 $ / shares shares
Second Quarter 2016 [Member]
Number of Shares \| shares	37,500
Exercise Price Lower Limit	$ 5.00
Remaining Life (years)	6 months
Third Quarter 2016 [Member]
Number of Shares \| shares	525,000
Exercise Price Lower Limit	$ 1.00
Exercise Price Upper Limit	$ 5.00
Remaining Life (years)	6 months
Third Quarter 2017 [Member]
Number of Shares \| shares	1,500,000
Exercise Price Lower Limit	$ 1.00
Remaining Life (years)	1 year 6 months
Fourth Quarter 2017 [Member]
Number of Shares \| shares	2,941,666
Exercise Price Lower Limit	$ 1.00
Exercise Price Upper Limit	$ 9.00
Remaining Life (years)	1 year 9 months
First Quarter 2018 [Member]
Number of Shares \| shares	127,500
Exercise Price Lower Limit	$ 15.00
Remaining Life (years)	2 years
Second Quarter 2018 [Member]
Number of Shares \| shares	33,334
Exercise Price Lower Limit	$ 15.00
Remaining Life (years)	2 years 3 months
Third Quarter 2018 [Member]
Number of Shares \| shares	650,000
Exercise Price Lower Limit	$ 1.00
Exercise Price Upper Limit	$ 1.50
Remaining Life (years)	2 years 6 months
Fourth Quarter 2018 [Member]
Number of Shares \| shares	1,197,500
Exercise Price Lower Limit	$ 1.00
Exercise Price Upper Limit	$ 1.50
Remaining Life (years)	2 years 9 months
First Quarter 2019 [Member]
Number of Shares \| shares	4,024,000
Exercise Price Lower Limit	$ 1.50
Exercise Price Upper Limit	$ 2.00
Remaining Life (years)	3 years
Second Quarter 2019 [Member]
Number of Shares \| shares	135,000
Exercise Price Lower Limit	$ 0.07
Exercise Price Upper Limit	$ 0.23
Remaining Life (years)	3 years 3 months
Third Quarter 2019 [Member]
Number of Shares \| shares	260,000
Exercise Price Lower Limit	$ .50
Remaining Life (years)	3 years 6 months
Fourth Quarter 2019 [Member]
Number of Shares \| shares	400,000
Exercise Price Lower Limit	$ .14
Remaining Life (years)	3 years 9 months
Second Quarter 2020 [Member]
Number of Shares \| shares	300,000
Exercise Price Lower Limit	$ .50
Remaining Life (years)	4 years 3 months
Second Quarter 2021 [Member]
Number of Shares \| shares	12,600,000
Exercise Price Lower Limit	$ 0.20
Remaining Life (years)	5 years

XML 46 R37.htm IDEA: XBRL DOCUMENT

Stock Compensation (Details Narrative) - USD ($)	3 Months Ended
Stock Compensation (Details Narrative) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Number of common stock issued for consulting fees	19,043,000	9,272,502
Fair value of common stock	$ 1,314,169	$ 1,712,876
Amortization of prepaid services	$ 669,667	$ 2,161,559
Minimum [Member]
Consulting fees amortized period	12 months
Maximum [Member]
Consulting fees amortized period	24 months

XML 47 R38.htm IDEA: XBRL DOCUMENT

Income Taxes - Results of Operations (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes - Results Of Operations Details Narrative
Effective tax rate	0.00%	0.00%
Deferred tax assets
Operating loss carryforwards	$ 66,500,000
Operating loss carryforwards expire term	expire in 2032-2035.

XML 48 R39.htm IDEA: XBRL DOCUMENT

Licenses and Supply Agreements (Details Narrative) - USD ($)						1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 24, 2014	Aug. 06, 2014	Dec. 24, 2012	Aug. 13, 2012	Apr. 24, 2012	May. 31, 2013	Mar. 31, 2016	Dec. 31, 2014	Dec. 31, 2013
Minimum royalty amount								$ 100,000
Issued common stock value							$ 1,314,169
Young Agreement [Member]
Patent liability									$ 118,333
Cost of the patent									$ 1,372,000
Smith Agreement [Member]
Number of shares acquired in exchange for common stock			300,000
Acquisition value			$ 2,880,384
Fair market value acquired			2,715,000
Payments for expenses			165,384
Number of common stock shares issued during period	1,000,000
Issued common stock value	$ 270,000
Smith Agreement [Member] \| Initial License Fee [Member]
Payments for expenses			100,000
Smith Agreement [Member] \| Expenses [Member]
Payments for expenses			$ 65,384
Shan Agreement [Member]
Number of common stock shares issued during period		500,000
Issued common stock value		$ 140,000
Number of shares issue upon final transfer of licenses						500,000
Dr. Plotnikoff [Member]
Number of shares acquired in exchange for common stock					8,000,000
TNI IP’s Management [Member]
Number of shares acquired in exchange for common stock					12,250,000
Acquisition value					$ 16,006,000
Dr. Bernard Bihari [Member] \| Young Agreement [Member]
Number of shares acquired in exchange for common stock				540,000
Acquisition value				$ 972,000
Assumed liabilities				$ 400,000
TNI BioTech IP, Inc. [Member]
Number of shares acquired in exchange for common stock					20,250,000
Acquisition value					$ 98,000,000

XML 49 R40.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($)					1 Months Ended			3 Months Ended		6 Months Ended	12 Months Ended
	Apr. 23, 2013	Oct. 18, 2012	Sep. 25, 2012	Jul. 14, 2012	Oct. 31, 2014	Feb. 28, 2014	Oct. 31, 2013	Mar. 31, 2016	Mar. 31, 2015	Oct. 31, 2015	Dec. 31, 2015
Letter of intent, description				the letter of intent, the Company and GBOIG intend to provide HIV/AIDS treatment to 25,000 patients and hopefully expanding to 500,000 within 24 months.
Initial capital to venture				$ 1,000
Percentage of allocated income from venture				50.00%
Cash rental expense								$ 53,205	$ 147,236
May 15, 2016 [Member]
Debt instruments installment								198,312
Orlando, Florida [Member]
Cash rental expense								$ (114,794)	$ 18,319
Plaintiff Claims [Member]
Seeking damages in excess						$ 75,000
Default judgment entered in favor of legal party amount										$ 80,000
Accrued for claim					$ 210,452
Withdrew from bank account towards settlement of claim										$ 92,590
Plaintiff EK Krause & Associates [Member]
Default judgment entered in favor of legal party amount						259,894
Accrued for claim						$ 279,000
GBOIG [Member]
Upfornt costs			$ 2,500,000
Distribution Agreements In Nigeria [Member]
Initial supply, description							Under the agreement, the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment.
Agreements With Hubei Qianjiang Pharmaceutical Company [Member]
Percentage of gross sales		6.00%
Agreements With Hubei Qianjiang Pharmaceutical Company [Member]
Initial supply, description	By either party upon provision of written notice at least 90 days before the end of the agreement, provided however that if the Company terminates the contract without cause it will be required to pay ViPharma a $10 million penalty.

XML 50 R41.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)	May. 01, 2016	Feb. 03, 2016	May. 16, 2016	Mar. 31, 2016	Dec. 31, 2015
Proceeds fom notes payable		$ 200,000
Common stock outstanding				205,127,530	174,850,047
Subsequent Event [Member]
Proceeds fom notes payable	$ 961,250
Repayments of notes payable	$ 245,000
Number of stock issued for debt conversion	1,786,285
Number of shares issued for consulting fees	450,000
Number of shares issued for debt conversion	836,285
Number of shares issued for loan orignation fees	500,000
Common stock outstanding			206,913,301
Mr. Wilson [Member] \| Subsequent Event [Member]
Annual base salary	$ 120,000

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end

XML 52 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 141 196 1 false 61 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://immunetherapeutics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://immunetherapeutics.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://immunetherapeutics.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://immunetherapeutics.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders??? Deficit (Unaudited) Sheet http://immunetherapeutics.com/role/StatementsOfStockholdersDeficit Condensed Consolidated Statements of Stockholders??? Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://immunetherapeutics.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Description of Business Sheet http://immunetherapeutics.com/role/OrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Property and Equipment Sheet http://immunetherapeutics.com/role/PropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 00000010 - Disclosure - Accrued Liabilities Sheet http://immunetherapeutics.com/role/AccruedLiabilities Accrued Liabilities Notes 10 false false R11.htm 00000011 - Disclosure - Notes Payable Notes http://immunetherapeutics.com/role/NotesPayable Notes Payable Notes 11 false false R12.htm 00000012 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants Sheet http://immunetherapeutics.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrants Capital Structure - Common Stock and Common Stock Purchase Warrants Notes 12 false false R13.htm 00000013 - Disclosure - Stock Compensation Sheet http://immunetherapeutics.com/role/StockCompensation Stock Compensation Notes 13 false false R14.htm 00000014 - Disclosure - Income Taxes - Results of Operations Sheet http://immunetherapeutics.com/role/IncomeTaxes-ResultsOfOperations Income Taxes - Results of Operations Notes 14 false false R15.htm 00000015 - Disclosure - Licenses and Supply Agreements Sheet http://immunetherapeutics.com/role/LicensesAndSupplyAgreements Licenses and Supply Agreements Notes 15 false false R16.htm 00000016 - Disclosure - Commitments and Contingencies Sheet http://immunetherapeutics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 00000017 - Disclosure - Subsequent Events Sheet http://immunetherapeutics.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 00000018 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - Property and Equipment (Tables) Sheet http://immunetherapeutics.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://immunetherapeutics.com/role/PropertyAndEquipment 20 false false R21.htm 00000021 - Disclosure - Accrued Liabilities (Tables) Sheet http://immunetherapeutics.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://immunetherapeutics.com/role/AccruedLiabilities 21 false false R22.htm 00000022 - Disclosure - Notes Payable (Tables) Notes http://immunetherapeutics.com/role/NotesPayableTables Notes Payable (Tables) Tables http://immunetherapeutics.com/role/NotesPayable 22 false false R23.htm 00000023 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants (Tables) Sheet http://immunetherapeutics.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrantsTables Capital Structure - Common Stock and Common Stock Purchase Warrants (Tables) Tables http://immunetherapeutics.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrants 23 false false R24.htm 00000024 - Disclosure - Organization and Description of Business (Details Narrative) Sheet http://immunetherapeutics.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative Organization and Description of Business (Details Narrative) Details http://immunetherapeutics.com/role/OrganizationAndDescriptionOfBusiness 24 false false R25.htm 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details) Sheet http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBasicAndDilutedNetLossPerShareDetails Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details) Details 26 false false R27.htm 00000027 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) Sheet http://immunetherapeutics.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfAntidilutiveSecuritiesDetails Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) Details 27 false false R28.htm 00000028 - Disclosure - Property and Equipment (Details Narrative) Sheet http://immunetherapeutics.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://immunetherapeutics.com/role/PropertyAndEquipmentTables 28 false false R29.htm 00000029 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://immunetherapeutics.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails Property and Equipment - Schedule of Property and Equipment (Details) Details 29 false false R30.htm 00000030 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) Sheet http://immunetherapeutics.com/role/AccruedLiabilities-ScheduleOfAccruedLiabilitiesDetails Accrued Liabilities - Schedule of Accrued Liabilities (Details) Details 30 false false R31.htm 00000031 - Disclosure - Notes Payable (Details Narrative) Notes http://immunetherapeutics.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://immunetherapeutics.com/role/NotesPayableTables 31 false false R32.htm 00000032 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) Notes http://immunetherapeutics.com/role/NotesPayable-ScheduleOfNotesPayableDetails Notes Payable - Schedule of Notes Payable (Details) Details 32 false false R33.htm 00000033 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Notes http://immunetherapeutics.com/role/NotesPayable-ScheduleOfNotesPayableDetailsParenthetical Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Details 33 false false R34.htm 00000034 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants (Details Narrative) Sheet http://immunetherapeutics.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrantsDetailsNarrative Capital Structure - Common Stock and Common Stock Purchase Warrants (Details Narrative) Details http://immunetherapeutics.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrantsTables 34 false false R35.htm 00000035 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details) Sheet http://immunetherapeutics.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrants-ScheduleOfOutstandingStockWarrantsDetails Capital Structure - Common Stock and Common Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details) Details 35 false false R36.htm 00000036 - Disclosure - Capital Structure - Common Stock and Common Stock Purchase Warrants - Summary of Outstanding Warrants (Details) Sheet http://immunetherapeutics.com/role/CapitalStructure-CommonStockAndCommonStockPurchaseWarrants-SummaryOfOutstandingWarrantsDetails Capital Structure - Common Stock and Common Stock Purchase Warrants - Summary of Outstanding Warrants (Details) Details 36 false false R37.htm 00000037 - Disclosure - Stock Compensation (Details Narrative) Sheet http://immunetherapeutics.com/role/StockCompensationDetailsNarrative Stock Compensation (Details Narrative) Details http://immunetherapeutics.com/role/StockCompensation 37 false false R38.htm 00000038 - Disclosure - Income Taxes - Results of Operations (Details Narrative) Sheet http://immunetherapeutics.com/role/IncomeTaxes-ResultsOfOperationsDetailsNarrative Income Taxes - Results of Operations (Details Narrative) Details http://immunetherapeutics.com/role/IncomeTaxes-ResultsOfOperations 38 false false R39.htm 00000039 - Disclosure - Licenses and Supply Agreements (Details Narrative) Sheet http://immunetherapeutics.com/role/LicensesAndSupplyAgreementsDetailsNarrative Licenses and Supply Agreements (Details Narrative) Details http://immunetherapeutics.com/role/LicensesAndSupplyAgreements 39 false false R40.htm 00000040 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://immunetherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://immunetherapeutics.com/role/CommitmentsAndContingencies 40 false false R41.htm 00000041 - Disclosure - Subsequent Events (Details Narrative) Sheet http://immunetherapeutics.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://immunetherapeutics.com/role/SubsequentEvents 41 false false All Reports Book All Reports imnp-20160331.xml imnp-20160331.xsd imnp-20160331_cal.xml imnp-20160331_def.xml imnp-20160331_lab.xml imnp-20160331_pre.xml true true ZIP 57 0001493152-16-009896-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-16-009896-xbrl.zip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end